Pembrolizumab

Monoclonal antibody

Also known as MK-3475

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma, Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma, Non-Muscle Invasive Bladder Cancer, Metastatic Colorectal Cancer, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Cervical Cancer, Hepatocellular Carcinoma, Biliary Tract Cancer, Merkel Cell Carcinoma, Renal Cell Carcinoma, Endometrial Cancer, Breast Cancer, Ovarian Cancer, Colorectal Cancer, Large B-Cell Lymphoma, Solid Tumors

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 3

Also approved (7)
US
  • Tumor Mutational Burden-High Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-authorized test [see Dosage and Administration (2.1) ] , that have progressed following prior treatment and who have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on tumor response rate and durability of response [see Clinical Studies (14.18) ] . Continued approval for this indication may
    Outside this platform's coverage
  • Malignant Pleural Mesothelioma KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic malignant pleural mesothelioma (MPM).Outside this platform's coverage
  • Classical Hodgkin Lymphoma KEYTRUDA is indicated for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). KEYTRUDA is indicated for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.
  • Microsatellite Instability-High or Mismatch Repair Deficient Cancer KEYTRUDA is indicated for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-authorized test, that have progressed following prior treatment and who have no satisfactory alternative treatment options [see Dosage and Administration (2.1) ] .
    Outside this platform's coverage
  • Cutaneous Squamous Cell Carcinoma KEYTRUDA is indicated for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC that is not curable by surgery or radiation.Outside this platform's coverage
Product first approved 2014FDA label
JP
  • Treatment of unresectable melanoma
Product first approved 2016PMDA
EU
  • Melanoma Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma. Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC, or with Stage III melanoma and lymph node involvement who have undergone complete resection. Non small cell lung carcinoma (NSCLC) Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for...
Product first approved 2015EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (201)
Biliary Tract Cancer
NCT06282575 · Jazz Pharmaceuticals
2024-07-19 – 2030-04-01 · Biliary Tract Cancer
What this study did
Breast Cancer
NCT06606730 · UNICANCER
2025-07-23 – 2039-06-01 · Breast Cancers, Triple Negative Breast Cancer (TNBC)
What this study did
NCT06393374 · Merck Sharp & Dohme LLC
2024-06-24 – 2037-12-14 · Triple-Negative Breast Cancer
What this study did
NCT07486687 · The Netherlands Cancer Institute
2026-04 – 2036-04 · Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
NCT05929768 · SWOG Cancer Research Network
2023-09-15 – 2033-04 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
What this study did
NCT07178730 · Women's Cancer Study Group GmbH
2026-08-30 – 2033-03-31 · Breast Cancer, Triple-negative Breast Cancer
What this study did
NCT06081244 · Women's Cancer Study Group GmbH
2024-10-10 – 2029-09 · Triple Negative Breast Cancer
What this study did
NCT02954874 · National Cancer Institute (NCI)
2017-01-18 – 2027-08-27 · Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
What this study did
NCT02555657 · Merck Sharp & Dohme LLC
2015-10-13 – 2020-11-10 · Metastatic Triple Negative Breast Cancer
What this study did
Cervical Cancer
NCT07061977 · National Cancer Institute (NCI)
2025-11-05 – 2030-12-31 · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IVA Cervical Cancer FIGO 2018
What this study did
Colorectal Cancer
NCT05239741 · Merck Sharp & Dohme LLC
2022-04-02 – 2028-09-19 · Colorectal Neoplasms
What this study did
Endometrial Cancer
NCT07684599 · GlaxoSmithKline
2026-09-24 – 2031-09-18 · Neoplasms, Endometrial
What this study did
NCT07198074 · National Cancer Institute (NCI)
2026-01-27 – 2028-07-01 · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
What this study did
NCT05077215 · Evergreen Therapeutics, Inc.
2026-12 – 2027-12 · Advanced Endometrial Cancer
What this study did
NCT04214067 · National Cancer Institute (NCI)
2020-04-09 – 2027-02-05 · Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
What this study did
Esophageal Squamous Cell Carcinoma
NCT04807673 · Tianjin Medical University Cancer Institute and Hospital
2021-12-01 – 2028-05 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04210115 · Merck Sharp & Dohme LLC
2020-02-28 – 2026-06-26 · Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)
What this study did
NCT04949256 · Merck Sharp & Dohme LLC
2021-07-28 – 2026-05-20 · Metastatic Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT07673887 · Astellas Pharma Global Development, Inc.
2026-07-28 – 2031-02-28 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
NCT06731478 · Daiichi Sankyo
2025-02-27 – 2030-02-01 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT06093425 · Transcenta Therapeutics (Hangzhou) Co., Ltd.
2027-06-30 – 2030-01-31 · Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer
What this study did
NCT03221426 · Merck Sharp & Dohme LLC
2017-10-09 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT04882241 · Merck Sharp & Dohme LLC
2020-07-29 – 2025-04-23 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07026474 · Universität des Saarlandes
2025-10-30 – 2032-12-31 · Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT06589804 · National Cancer Institute (NCI)
2025-03-27 – 2032-12-25 · Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Refractory Head and Neck Squamous Cell Carcinoma, Refractory Hypopharyngeal Squamous Cell Carcinoma, Refractory Laryngeal Squamous Cell Carcinoma, Refractory Oral Cavity Squamous Cell Carcinoma, Refractory Oropharyngeal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT07509099 · Ji Dongmei
2026-09-15 – 2031-09-30 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06102395 · Beijing Tongren Hospital
2023-05-01 – 2030-04-30 · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab
What this study did
NCT05721755 · ECOG-ACRIN Cancer Research Group
2023-06-08 – 2030-03-31 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT07276399 · Janssen Research & Development, LLC
2025-12-03 – 2029-07-18 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT06699212 · Rakuten Medical, Inc.
2024-12-24 – 2028-09 · Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT06998069 · Brown University
2025-08-27 – 2027-06-01 · Head and Neck Neoplasms
What this study did
NCT06790966 · PDS Biotechnology Corp.
2025-05-30 – 2026-08-25 · Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
What this study did
Phase 2/3 (20)
Biliary Tract Cancer
NCT05429697 · SMT bio Co., Ltd.
2022-06-09 – 2026-06-08 · Biliary Tract Cancer
What this study did
Esophageal Squamous Cell Carcinoma
NCT06907602 · Peking Union Medical College Hospital
2024-01-12 – 2028-12-31 · Locally Advanced Esophageal Squamous Cell Carcinoma
What this study did
Head and Neck Squamous Cell Carcinoma
NCT03755739 · Second Affiliated Hospital of Guangzhou Medical University
2018-11-01 – 2036-11-01 · Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer, Cervical Cancer, Breast Cancer
What this study did
NCT04969861 · Nektar Therapeutics
2022-03-09 – 2022-04-22 · Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
What this study did
Melanoma
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04613596 · Mirati Therapeutics Inc.
2020-12-02 – 2029-10-31 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
What this study did
NCT05255302 · Intergroupe Francophone de Cancerologie Thoracique
2022-05-02 – 2029-06-01 · Metastatic NSCLC
What this study did
NCT05096663 · SWOG Cancer Research Network
2022-03-15 – 2027-12-01 · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT04750083 · Taizhou Hanzhong biomedical co. LTD
2020-09-25 – 2023-09-25 · Nonsquamous Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT06493552 · Vasgene Therapeutics, Inc
2025-03-15 – 2034-08 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
What this study did
Other / comorbidity
NCT06513884 · Hookipa Biotech GmbH
2024-12 – 2032-04 · Oropharyngeal Squamous Cell Carcinoma Recurrent
What this study did
NCT07572123 · National Cancer Institute (NCI)
2026-12-04 – 2029-03-31 · Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
What this study did
NCT06923475 · Amsterdam UMC, location VUmc
2026-04-17 – 2028-11-06 · Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable, Borderline Resectable
What this study did
NCT06276504 · Assistance Publique - Hôpitaux de Paris
2024-04 – 2028-04 · Progressive Multifocal Leukoencephalopathy
What this study did
NCT04093167 · Canadian Cancer Trials Group
2020-05-26 – 2027-07-30 · Lung Cancer
What this study did
NCT06295809 · Merck Sharp & Dohme LLC
2024-04-18 – 2026-03-05 · Carcinoma, Squamous Cell, Skin Neoplasms
What this study did
NCT04887870 · Mirati Therapeutics Inc.
2021-06-29 – 2025-09-25 · Advanced or Metastatic Solid Malignancies
What this study did
NCT02784171 · Canadian Cancer Trials Group
2016-11-11 – 2024-10-11 · Mesothelioma
What this study did
Phase 2 (1113)
Biliary Tract Cancer
NCT07850791 · Haitao Zhao, MD
2026-10 – 2029-12 · Biliary Tract Cancer (BTC)
What this study did
NCT06001658 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-07-08 – 2028-06 · Billiary Track Cancer
What this study did
NCT07159217 · Peking Union Medical College Hospital
2025-08-30 – 2028-05-31 · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib, Immune Checkpoint Inhibitors
What this study did
NCT06978114 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-06-10 – 2027-12 · Advanced Biliary Tract Cancer
What this study did
NCT06178445 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2024-04-17 – 2027-07 · Biliary Tract Cancer, HER2 Gene Mutation, HER2
What this study did
NCT06708858 · Dai, Guanghai
2024-08-15 – 2027-07 · Advanced Biliary Tract Cancer
What this study did
NCT06230471 · Peking Union Medical College Hospital
2023-01-09 – 2026-04-30 · Biliary Tract Neoplasms Immunotherapy
What this study did
NCT05998447 · Genome & Company
2023-09-18 – 2024-11-26 · Biliary Tract Cancer
What this study did
NCT03797326 · Merck Sharp & Dohme LLC
2019-02-12 – 2024-10-28 · Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer
What this study did
NCT03260712 · European Organisation for Research and Treatment of Cancer - EORTC
2020-01-07 – 2023-08-31 · Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer, Gallbladder Cancer
What this study did
Breast Cancer
NCT07552181 · Yuan Yuan
2026-09 – 2035-09 · TNBC - Triple-Negative Breast Cancer, TNBC, Early Stage Triple-Negative Breast Carcinoma
What this study did
NCT07743190 · Medical University of South Carolina
2027-01-01 – 2034-05-29 · Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
What this study did
NCT07015853 · Stephen Shiao
2026-12 – 2033-12 · TNBC - Triple-Negative Breast Cancer, Breast Cancer
What this study did
NCT07016399 · Vandana Abramson
2025-09-09 – 2033-10 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT07914309 · Washington University School of Medicine
2026-11-30 – 2033-05-31 · Triple Negative Breast Cancer, Triple Negative Breast Cancer (TNBC), Breast Cancer
What this study did
NCT07857486 · Institut Paoli-Calmettes
2026-11 – 2032-11 · Early Triple-Negative Breast Cancer
What this study did
NCT06078384 · UNICANCER
2024-12-27 – 2032-01-01 · Triple-negative Breast Cancer
What this study did
NCT07276880 · UNC Lineberger Comprehensive Cancer Center
2026-03-17 – 2032-01 · Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-Negative Breast Carcinoma, Node-positive Breast Cancer
What this study did
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT06829199 · Merck Sharp & Dohme LLC
2025-03-26 – 2031-03-18 · Early Triple Negative Breast Cancer
What this study did
NCT07610525 · M.D. Anderson Cancer Center
2026-11-05 – 2031-01-15 · Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
What this study did
NCT07786428 · University of Texas Southwestern Medical Center
2026-10-01 – 2030-10-31 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT06245889 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-05-01 – 2030-06 · Triple Negative Breast Cancer
What this study did
NCT05255666 · Washington University School of Medicine
2023-07-31 – 2030-01-31 · Triple Negative Breast Cancer, Brain Metastases
What this study did
NCT03747120 · University of Texas Southwestern Medical Center
2019-01-25 – 2029-12 · HER2-positive Breast Cancer, Breast Cancer
What this study did
NCT05020860 · Baylor Breast Care Center
2023-04-18 – 2029-11 · Breast Cancer, Breast Neoplasm, Breast Cancer Female, Breast Cancer Invasive, Breast Cancer Stage II, Breast Cancer Stage III, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Neoplasms, Estrogen Receptor-positive Breast Cancer
What this study did
NCT04230109 · Massachusetts General Hospital
2020-07-14 – 2029-10 · Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT06976944 · Yukinori Ozaki
2025-06-24 – 2029-09 · Recurrent Triple-Negative Breast Cancer
What this study did
NCT05741164 · Emory University
2024-09-01 – 2029-06-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT03546686 · University of Texas Southwestern Medical Center
2019-11-12 – 2029-06 · Breast Cancer
What this study did
NCT06353997 · Providence Health & Services
2024-09-05 – 2029-06 · Triple Negative Breast Cancer
What this study did
NCT04468061 · Dana-Farber Cancer Institute
2020-07-20 – 2029-04-01 · Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
What this study did
NCT07188246 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2026-01-19 – 2029-02 · Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive, Breast Cancer Triple Negative
What this study did
NCT02411656 · M.D. Anderson Cancer Center
2015-06-11 – 2028-12-31 · Edema, Erythema, Estrogen Receptor Negative, HER2/Neu Negative, Peau d'Orange, Progesterone Receptor Negative, Recurrent Inflammatory Breast Carcinoma, Stage IV Inflammatory Breast Carcinoma, Triple-Negative Breast Carcinoma
What this study did
NCT07862751 · Emory University
2027-01-01 – 2028-12-31 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT05645380 · University of Kansas Medical Center
2022-12-05 – 2028-12 · Triple Negative Breast Cancer, Breast Cancer
What this study did
NCT06845319 · Medical University of South Carolina
2025-10-20 – 2028-10-20 · Triple Negative Breast Cancer
What this study did
NCT05485766 · Okayama University
2024-07-16 – 2028-09-30 · Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, BRCA-Associated Breast Carcinoma
What this study did
NCT07407920 · M.D. Anderson Cancer Center
2025-10-09 – 2028-09-30 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
What this study did
NCT05973864 · UNICANCER
2025-03-11 – 2028-08 · Triple Negative Breast Neoplasms
What this study did
NCT07054242 · Yantai Yuhuangding Hospital
2025-10-30 – 2028-06-30 · Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer
What this study did
NCT04348747 · Roswell Park Cancer Institute
2022-12-19 – 2028-05-15 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT06492759 · Emory University
2025-10-22 – 2028-02-13 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT06407310 · Tel Aviv Medical Center
2024-07-01 – 2027-12-01 · Triple Negative Breast Cancer
What this study did
NCT06318897 · M.D. Anderson Cancer Center
2024-05-29 – 2027-09-30 · Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
What this study did
NCT06027268 · Wake Forest University Health Sciences
2024-01-10 – 2027-08 · Metastatic Triple-Negative Breast Cancer
What this study did
NCT02957968 · Virginia Commonwealth University
2017-01-24 – 2027-03-31 · Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Progesterone Receptor Positive Tumor, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-negative Breast Carcinoma
What this study did
NCT05539365 · Roswell Park Cancer Institute
2025-02-01 – 2027-02-01 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
Phase 1/2 (419)
Biliary Tract Cancer
NCT06428409 · Merck Sharp & Dohme LLC
2024-06-20 – 2029-10-16 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer
What this study did
NCT07269158 · Yonsei University
2025-12 – 2029-09 · Biliary Tract Neoplasms, Advanced Cancer, Immunotherapy
What this study did
NCT05482893 · Phanes Therapeutics
2023-03-15 – 2028-04 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Colorectal Cancer
What this study did
NCT03937895 · SMT bio Co., Ltd.
2019-12-03 – 2021-06-08 · Biliary Tract Cancer
What this study did
Breast Cancer
NCT06134375 · Dartmouth-Hitchcock Medical Center
2024-11-26 – 2036-06-26 · Triple Negative Breast Cancer, Residual Disease
What this study did
NCT05491083 · National University Hospital, Singapore
2023-06-12 – 2026-12-31 · Advanced Solid Tumor, Triple Negative Breast Cancer
What this study did
NCT06880029 · Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
2024-09-01 – 2025-09-01 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT05756166 · Roswell Park Cancer Institute
2024-02-16 – 2025-06-19 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT03310957 · Seagen Inc.
2018-02-27 – 2024-09-30 · Triple Negative Breast Neoplasms
What this study did
NCT04512261 · Reva Basho
2022-06-01 – 2024-06-01 · Breast Cancer, Brain Metastases, HER2-positive Breast Cancer, CNS Disease
What this study did
NCT03752723 · Genexine, Inc.
2019-03-27 – 2023-05-11 · Triple Negative Breast Cancer
What this study did
NCT03106415 · Mayo Clinic
2017-09-27 – 2022-05-19 · Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT02129556 · ETOP IBCSG Partners Foundation
2014-12 – 2017-08-04 · Metastatic Breast Cancer
What this study did
Cervical Cancer
NCT06543576 · Jonsson Comprehensive Cancer Center
2025-07-29 – 2032-01-31 · Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
What this study did
NCT03786081 · Seagen, a wholly owned subsidiary of Pfizer
2019-02-27 – 2026-03-19 · Cervical Cancer
What this study did
NCT03444376 · Genexine, Inc.
2018-06-19 – 2023-12-21 · Cervical Cancer
What this study did
Colorectal Cancer
NCT07591597 · National Cancer Center Hospital East
2026-05 – 2029-05 · Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
What this study did
NCT06530303 · Essen Biotech
2024-09-29 – 2026-12-28 · Colorectal Cancer, Colon Cancer, Rectum Cancer
What this study did
NCT04014530 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2019-08-01 – 2023-08-01 · Colorectal Cancer, Endometrium Cancer
What this study did
NCT03761914 · Sellas Life Sciences Group
2019-09-30 – 2022-10-27 · Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
What this study did
NCT03332498 · H. Lee Moffitt Cancer Center and Research Institute
2018-01-24 – 2021-09-09 · Colon Cancer, Colorectal Cancer, Colorectal Carcinoma, Colon Disease
What this study did
NCT02713373 · Roswell Park Cancer Institute
2016-08-05 – 2021-07-20 · Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
What this study did
Endometrial Cancer
NCT07262619 · Eikon Therapeutics
2026-01-20 – 2029-03 · Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
What this study did
NCT06253494 · National Cancer Institute (NCI)
2024-05-14 – 2028-12-31 · Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
What this study did
NCT05572684 · NextCure, Inc.
2022-10-06 – 2025-04-30 · Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable, Ovarian Cancer, Gastric Cancer, Colo-rectal Cancer, Esophageal Cancer, Endometrial Cancer, Head Neck Cancer, Cervical Cancer, Lung Cancer
What this study did
Esophageal Squamous Cell Carcinoma
NCT06780111 · Merck Sharp & Dohme LLC
2025-07-30 – 2032-01-04 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05342636 · Merck Sharp & Dohme LLC
2022-07-27 – 2025-12-05 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT05541445 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2022-08-01 – 2024-12-01 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT05438459 · Kyushu University
2022-06-08 – 2032-03-31 · Gastric Cancer, Pancreatic Cancer
What this study did
NCT06116136 · Servier Bio-Innovation LLC
2024-08-31 – 2027-08 · MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
What this study did
NCT04592211 · Yonsei University
2021-10-01 – 2026-05-31 · Gastric Cancer Stage IV
What this study did
NCT05508737 · Yonsei University
2022-12-01 – 2025-12-01 · Gastric and Gastroesophageal Junction Adenocarcinoma
What this study did
NCT04727151 · Triumvira Immunologics, Inc.
2021-04-19 – 2024-03-25 · HER2 Positive Gastric Cancer, Metastatic HER2 Positive Gastroesophageal Junction Cancer
What this study did
NCT02730546 · Mayo Clinic
2016-06-24 – 2023-10-31 · Gastric Cardia Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Gastric Cancer AJCC v7, Stage II Gastric Cancer AJCC v7, Stage IIA Gastric Cancer AJCC v7, Stage IIB Gastric Cancer AJCC v7, Stage IIIA Gastric Cancer AJCC v7, Stage IIIB Gastric Cancer AJCC v7
What this study did
NCT03918499 · City of Hope Medical Center
2019-04-30 – 2023-02-09 · Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma
What this study did
NCT02901301 · Yonsei University
2017-02-06 – 2021-10 · Gastric Cancer
What this study did
NCT02689284 · MacroGenics
2016-01 – 2021-01 · Gastric Cancer, Stomach Cancer, Esophageal Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT05187338 · Second Affiliated Hospital of Guangzhou Medical University
2021-11-01 – 2035-10-30 · Lung Cancer, Liver Cancer, Colorectal Cancer, Pancreas Cancer, Ovary Cancer, Head and Neck Cancer, Breast Cancer, Gastric Cancer, Cervical Cancer, Esophageal Cancer, Sarcoma
What this study did
NCT07552558 · Washington University School of Medicine
2026-11-30 – 2034-01-31 · Head and Neck Squamous Cell Carcinoma, HPV-Negative Squamous Cell Carcinoma
What this study did
NCT06385080 · Janssen Research & Development, LLC
2024-04-22 – 2033-07-28 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT04198766 · Inhibrx Biosciences, Inc
2019-12-10 – 2033-07 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma, Resectable Non-Small-Cell Lung Cancer
What this study did
NCT05784688 · TiumBio Co., Ltd.
2023-03-10 – 2028-12 · Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
What this study did
NCT03526835 · Genmab
2018-05-02 – 2028-11 · Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
What this study did
NCT06265025 · GeneMedicine Co., Ltd.
2024-02-20 – 2028-10-30 · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma, Cervical Cancer, Breast Cancer
What this study did
NCT05086692 · Medicenna Therapeutics, Inc.
2021-08-27 – 2028-10-20 · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
What this study did
NCT06747585 · Alentis Therapeutics AG
2024-12-16 – 2028-08-15 · Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
What this study did
Phase 1 (570)
Breast Cancer
NCT07300475 · Washington University School of Medicine
2026-12-01 – 2035-08-31 · Triple Negative Breast Cancer
What this study did
NCT07341867 · Andrew Hantel, MD
2026-07-30 – 2029-03-31 · Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
What this study did
NCT07652242 · Immunomic Therapeutics, Inc.
2026-07-14 – 2028-08 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT03362060 · Massachusetts General Hospital
2017-12-12 – 2027-12-30 · Triple Negative Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04427293 · University of Illinois at Chicago
2020-07-09 – 2027-07 · Triple Negative Breast Cancer
What this study did
NCT04265872 · Baylor Research Institute
2020-10-15 – 2027-03-31 · Breast Cancer
What this study did
NCT05422794 · National Cancer Institute (NCI)
2023-05-18 – 2027-03-31 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT06637306 · Rima Patel
2025-03-05 – 2027-03-10 · Locally Advanced Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
What this study did
NCT05673200 · National Cancer Institute (NCI)
2023-09-25 – 2027-02-23 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT06324240 · Emory University
2025-12-02 – 2026-12-31 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT06351332 · Filipa Lynce, MD
2024-05-01 – 2026-02-24 · Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
What this study did
NCT02977468 · Columbia University
2017-10-25 – 2024-07-18 · Triple Negative Breast Cancer
What this study did
NCT03599453 · Roswell Park Cancer Institute
2019-01-09 – 2023-03-21 · Triple -Negative Breast Cancer, Estrogen Receptor Negative, HER2/Neu Negative, Anatomic Stage IV Breast Cancer AJCC, Progesterone Receptor Negative
What this study did
NCT03012230 · Mayo Clinic
2017-12-06 – 2023-03-08 · Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
What this study did
NCT05093387 · Northwestern University
2022-11-10 – 2022-11-10 · Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT03720431 · PharmAbcine
2019-01-03 – 2022-10-26 · Triple Negative Breast Cancer
What this study did
NCT03197389 · Universitaire Ziekenhuizen KU Leuven
2018-01-18 – 2020-03-31 · Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Negative Neoplasm
What this study did
Cervical Cancer
NCT05082259 · Institute of Cancer Research, United Kingdom
2022-03-02 – 2026-12 · Advanced Cancer, Cervical Cancer, Triple Negative Breast Cancer
What this study did
Colorectal Cancer
NCT05746897 · Hefei TG ImmunoPharma Co., Ltd.
2023-04-13 – 2027-09-30 · Ovarian Cancer, Melanoma, Triple Negative Breast Cancer, Colorectal Cancer
What this study did
NCT05838768 · Novartis Pharmaceuticals
2023-06-27 – 2027-08-31 · MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
What this study did
NCT02600949 · M.D. Anderson Cancer Center
2016-05-11 – 2027-05-31 · Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
NCT06004245 · Vividion Therapeutics, Inc.
2024-01-25 – 2027-05-31 · Advanced Solid Tumors, Colorectal Cancer
What this study did
NCT05446129 · Boehringer Ingelheim
2022-09-27 – 2023-11-08 · Colorectal Cancer
What this study did
NCT03658772 · Arrys Therapeutics
2018-09-20 – 2023-03-07 · Microsatellite Stable Colorectal Cancer
What this study did
NCT02972034 · Merck Sharp & Dohme LLC
2017-01-13 – 2022-12-02 · Neoplasms, Colorectal Cancer
What this study did
NCT02512172 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-02-19 – 2021-11-20 · Colorectal Cancer
What this study did
NCT03095781 · Emory University
2017-07-07 – 2021-06-10 · Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Colorectal Cancer, Stage III Pancreatic Cancer, Stage IIIA Colorectal Cancer, Stage IIIB Colorectal Cancer, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Pancreatic Carcinoma
What this study did
NCT02757391 · M.D. Anderson Cancer Center
2019-08-09 – 2020-10-02 · Colorectal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
What this study did
Endometrial Cancer
NCT03932409 · University of Oklahoma
2020-02-19 – 2027-06-25 · Endometrial Cancer
What this study did
NCT04611139 · HonorHealth Research Institute
2021-12-31 – 2024-06-30 · SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer
What this study did
NCT03694834 · UNC Lineberger Comprehensive Cancer Center
2019-03-29 – 2023-10-23 · Endometrial Cancer, Uterine Cancer
What this study did
NCT02728830 · AA Secord
2016-06 – 2022-01-31 · Gynecologic Neoplasms, Epithelial Ovarian Cancer, Uterine Endometrial Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT02630823 · Washington University School of Medicine
2016-02-05 – 2020-10-03 · Endometrial Cancer, Endometrial Carcinoma, Neoplasms, Endometrial
What this study did
Esophageal Squamous Cell Carcinoma
NCT03792347 · Hecheng Li M.D., Ph.D
2019-01-21 – 2020-06-17 · Esophageal Squamous Cell Carcinoma
What this study did
Gastric Cancer
NCT05187182 · Washington University School of Medicine
2023-06-02 – 2029-04-30 · Gastric Cancer, Esophageal Cancer, Stomach Cancer, Esophagus Cancer, Gastroesophageal Junction Cancer
What this study did
NCT05041153 · M.D. Anderson Cancer Center
2022-02-14 – 2026-12-30 · Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT03395847 · M.D. Anderson Cancer Center
2018-02-09 – 2023-01-27 · Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastric Cancer AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastric Cancer AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastric Cancer AJCC v8, Pathologic Stage IIIC Gastric Cancer AJCC v8, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04044859 · USWM CT, LLC
2019-08-20 – 2037-04-30 · Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer, Head and Neck Cancer, Melanoma, Ovarian Cancer, Non-small Cell Lung (NSCLC), Urothelial Cancer
What this study did
NCT04266730 · UNC Lineberger Comprehensive Cancer Center
2027-05-20 – 2033-06-01 · Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
What this study did
NCT07090499 · Pfizer
2025-08-20 – 2029-07-08 · Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
What this study did
NCT04389632 · Seagen, a wholly owned subsidiary of Pfizer
2020-06-08 – 2029-03-22 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
What this study did
NCT05208762 · Seagen, a wholly owned subsidiary of Pfizer
2022-10-25 – 2029-01-04 · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma, Triple Negative Breast Neoplasms, Gastric Cancer, Endometrial Cancer, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma
What this study did
NCT06868433 · Emory University
2025-05-08 – 2028-12-31 · Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
What this study did
NCT05859074 · Memorial Sloan Kettering Cancer Center
2023-05-04 – 2028-05-04 · Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC, BCC - Basal Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Sebaceous Carcinoma, Extramammary Paget Disease, Kaposi Sarcoma, Head and Neck Squamous Cell Carcinoma, HNSCC, Adnexal Carcinoma, Angiosarcoma, Cutaneous Neoplasm, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Solid Tumor
What this study did
NCT07227168 · Sutro Biopharma, Inc.
2025-11-07 – 2028-04 · Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer, Gastric Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Cervical Cancer, Endometrial Cancer, Urothelial Cancer
What this study did
NCT04429542 · Bicara Therapeutics
2020-06-01 – 2028-03-30 · Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
What this study did
NCT07501650 · Thomas Jefferson University
2026-03-18 – 2028-03 · Head and Neck Cancer, Head and Neck Small Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
What this study did
Phase 4 (16)
Breast Cancer
NCT06920810 · Ilsan Cha hospital
2025-03-19 – 2028-12-31 · Breast Cancer, Triple Negative Breast Cancer
What this study did
Cervical Cancer
NCT07645625 · University Medical Center Groningen
2026-05-11 – 2039-02 · Cervical Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07633613 · Centre Antoine Lacassagne
2026-10 – 2029-05 · Non-Small Cell Lung Carcinoma (NSCLC), Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT04489888 · Merck Sharp & Dohme LLC
2020-10-27 – 2024-06-28 · Squamous Cell Carcinoma of Head and Neck
What this study did
Non-Small Cell Lung Cancer
NCT03715205 · Merck Sharp & Dohme LLC
2019-01-31 – 2024-08-21 · Carcinoma, Non-Small-Cell Lung, Melanoma
What this study did
NCT03134456 · Samsung Medical Center
2018-05-14 – 2023-07-13 · Metastatic Non-Small Cell Lung Carcinoma
What this study did
Renal Cell Carcinoma
NCT07872553 · Memorial Sloan Kettering Cancer Center
2026-09-24 – 2030-09-24 · Renal Cell Carcinoma, Kidney Cancer
What this study did
Solid Tumors
NCT06824792 · NING LI
2025-03-01 – 2030-02-28 · Advanced Solid Tumors
What this study did
Urothelial Carcinoma
NCT06764095 · Mayo Clinic
2025-01-08 – 2032-01-01 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis and Ureter Cancer AJCC v8
What this study did
Other / comorbidity
NCT07801027 · Merck Sharp & Dohme LLC
2026-11-06 – 2030-01-31 · Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical Neoplasms
What this study did
NCT07010393 · Fujian Medical University
2025-07-01 – 2028-12-31 · Thyroid Neoplasms
What this study did
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT05235737 · Medical University of Silesia
2022-03-01 – 2026-05-30 · Newly Diagnosed Glioblastoma
What this study did
NCT04554524 · Tang-Du Hospital
2020-08-27 – 2024-07-30 · Thymoma and Thymic Carcinoma
What this study did
NCT03891979 · NYU Langone Health
2019-06-25 – 2020-06-01 · Pancreatic Cancer
What this study did
Early phase / not applicable (27)
Biliary Tract Cancer
NCT07853690 · NYU Langone Health
2026-10-05 – 2028-09 · Biliary Track Cancer
What this study did
Cervical Cancer
NCT04555226 · Chongqing University Cancer Hospital
2021-01-11 – 2032-08 · Cervical Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT05047094 · Alpha Tau Medical LTD.
2021-11-02 – 2027-06 · Head and Neck Squamous Cell Carcinoma, Skin Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma
What this study did
NCT05821751 · Fondazione del Piemonte per l'Oncologia
2021-12-02 – 2025-12-02 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT04453046 · Aethlon Medical Inc.
2020-10-22 – 2022-11-14 · Squamous Cell Carcinoma of the Head and Neck
What this study did
Hepatocellular Carcinoma
NCT04425226 · RenJi Hospital
2020-08-06 – 2024-12-30 · Liver Transplant; Complications, Hepatocellular Carcinoma Recurrent
What this study did
Melanoma
NCT07422779 · Institute of Oncology Ljubljana
2022-03-01 – 2028-03-31 · Metastatic Melanoma, Skin Cancer
What this study did
NCT04513028 · Kelly McMasters
2020-11-03 – 2027-01-15 · Melanoma Stage III, Melanoma Stage IV
What this study did
NCT07436390 · Institute of Oncology Ljubljana
2024-03-31 – 2024-03-31 · Metastatic Melanoma, Malignant Melanoma, Skin Cancer
What this study did
Metastatic Colorectal Cancer
NCT06823323 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-01 – 2026-06-01 · Metastatic Colorectal Cancer (CRC)
What this study did
Non-Small Cell Lung Cancer
NCT03769129 · Second Affiliated Hospital of Guangzhou Medical University
2018-11-01 – 2029-11-01 · Non Small Cell Lung Cancer
What this study did
NCT02194738 · National Cancer Institute (NCI)
2014-09-26 – 2027-09-21 · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8
What this study did
NCT06000358 · Lithuanian University of Health Sciences
2023-04-01 – 2026-03-31 · Lung Cancer Stage IV
What this study did
NCT03832348 · Centre Henri Becquerel
2019-06-17 – 2024-07-03 · Non Small Cell Lung Cancer
What this study did
NCT04393883 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-04-01 – 2023-07-01 · Non-small-lung-cell Cancer, NSCLC, Pembrolizumab
What this study did
NCT04793815 · Centre hospitalier de l'Université de Montréal (CHUM)
2021-05-01 – 2023-06-27 · Non-small Cell Lung Cancer Metastatic, Cryotherapy Effect
What this study did
NCT02760225 · University Medical Center Groningen
2016-10-24 – 2020-09 · Melanoma, Non-small Cell Lung Cancer
What this study did
Ovarian Cancer
NCT05368207 · University Health Network, Toronto
2021-12-06 – 2025-10-16 · Small Cell Carcinoma, Hypercalcaemic Type, Ovarian Cancer
What this study did
Urothelial Carcinoma
NCT07629700 · University of Florence
2026-09-01 – 2028-09-01 · Urothelial Carcinoma (UC), Peripheral Nerve Disease
What this study did
NCT07548476 · Dana-Farber Cancer Institute
2026-09-03 – 2028-08 · Metastatic Bladder Cancer, Peripheral Neuropathy, Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Bladder Cancer, Urothelial Cancer
What this study did
Other / comorbidity
NCT07343596 · University of Wisconsin, Madison
2026-04-15 – 2027-12 · Oral Cavity Cancer
What this study did
NCT02658279 · Memorial Sloan Kettering Cancer Center
2016-01-22 – 2027-01 · Glioma, Recurrent Malignant Glioma
What this study did
NCT05745233 · China Medical University Hospital
2021-01-01 – 2026-12 · Malignant Ascites
What this study did
NCT05352165 · Shanghai Minimally Invasive Surgery Center
2023-01-01 – 2025-12-31 · Neoadjuvant Therapy
What this study did
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT02489357 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2015-12-11 – 2017-11-30 · Stage IV Prostate Cancer
What this study did
Used as active comparator (108)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (66)
Biliary Tract Cancer
NCT07710885 · Taiho Pharmaceutical Co., Ltd.
2026-06-24 – 2031-12-31 · Biliary Tract Cancer
What this study did
Breast Cancer
NCT05812807 · Alliance for Clinical Trials in Oncology
2023-06-14 – 2033-05-31 · Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
What this study did
NCT07679360 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-09-02 – 2032-12 · Triple Negative Breast Cancer
What this study did
Endometrial Cancer
Gastric Cancer
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06532006 · Shanghai Henlius Biotech
2024-11-22 – 2028-09-01 · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07264075 · Groupe Oncologie Radiotherapie Tete et Cou
2026-05-05 – 2030-05 · Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
What this study did
Melanoma
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT06264180 · Replimune, Inc.
2024-07-11 – 2031-03-31 · Advanced Melanoma
What this study did
NCT05647954 · Taizhou Hanzhong biomedical co. LTD
2022-12-31 – 2025-06-30 · Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms
What this study did
NCT03273153 · Hoffmann-La Roche
2017-12-11 – 2021-02-19 · Advanced BRAFV600 Wild-type Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07195695 · Boehringer Ingelheim
2026-01-16 – 2036-09-02 · Non-small Cell Lung Cancer
What this study did
NCT07222566 · Pfizer
2026-01-06 – 2032-08-26 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC), Metastatic Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT06890598 · Eli Lilly and Company
2025-03-27 – 2032-02 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT07672223 · CSPC Megalith Biopharmaceutical Co.,Ltd.
2026-07-30 – 2031-11-30 · Non-small Cell Lung Cancer
What this study did
NCT07715396 · AIO-Studien-gGmbH
2026-10-30 – 2031-10-30 · Non-small Cell Lung Cancer Metastatic
What this study did
NCT07361510 · Bristol-Myers Squibb
2026-03-12 – 2031-10-14 · Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT06868277 · AstraZeneca
2025-04-10 – 2030-12-02 · Carcinoma, Non-Small Cell Lung
What this study did
NCT06627647 · AstraZeneca
2024-11-27 – 2030-11-18 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT04194944 · Eli Lilly and Company
2020-02-17 – 2030-06 · Non-Small Cell Lung Cancer
What this study did
NCT05899608 · Summit Therapeutics
2023-10-26 – 2029-12-31 · Non-Small Cell Lung Cancer
What this study did
NCT07362459 · Sinocelltech Ltd.
2025-12-30 – 2029-09 · Non-Small Cell Lung Carcinoma (NSCLC)
What this study did
NCT06767514 · Summit Therapeutics
2025-02-27 – 2029-06 · Non-Small Cell Lung Cancer
What this study did
NCT05502237 · Gilead Sciences
2022-10-12 – 2029-01 · Non-small Cell Lung Cancer
What this study did
NCT06908993 · Intergroupe Francophone de Cancerologie Thoracique
2025-12-09 – 2028-07-15 · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
What this study did
NCT06939595 · Celltrion
2025-01-30 – 2028-07 · Non Squamous Non Small Cell Lung Cancer
What this study did
NCT06151574 · Boehringer Ingelheim
2024-02-09 – 2028-01-28 · Lung Cancer, Non-squamous, Non-small Cell
What this study did
NCT06847334 · Shanghai Henlius Biotech
2025-04-27 – 2028-01-24 · Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT07178795 · Sichuan Baili Pharmaceutical Co., Ltd.
2025-09-29 – 2027-12 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT05984277 · AstraZeneca
2023-10-24 – 2027-11-12 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT05048797 · AstraZeneca
2021-10-28 – 2027-07-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT06698042 · Merck Sharp & Dohme LLC
2024-11-21 – 2027-04-17 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT05499390 · Akeso
2022-11-09 – 2026-12-31 · Advanced Non-small-cell Lung Cancer
What this study did
NCT06430866 · Amgen
2024-09-12 – 2026-12-14 · Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT06754644 · Qilu Pharmaceutical Co., Ltd.
2025-01-15 – 2026-12 · NSCLC
What this study did
Phase 2/3 (9)
Biliary Tract Cancer
NCT07765433 · ECOG-ACRIN Cancer Research Group
2027-01-11 – 2029-12-31 · Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Locally Advanced Unresectable Gallbladder Adenocarcinoma, Metastatic Biliary Tract Adenocarcinoma, Metastatic Extrahepatic Cholangiocarcinoma, Metastatic Gallbladder Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Adenocarcinoma, Unresectable Extrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
Melanoma
NCT05987332 · IDEAYA Biosciences
2023-10-31 – 2028-01-15 · Metastatic Uveal Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07865910 · Shanghai Henlius Biotech
2026-11-30 – 2031-12-30 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
NCT06712316 · BioNTech SE
2025-01-07 – 2031-12 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT07815665 · Summit Therapeutics
2026-09-10 – 2030-12-31 · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)
What this study did
Phase 2 (21)
Breast Cancer
Gastric Cancer
NCT07788664 · Vall d'Hebron Institute of Oncology
2026-12-01 – 2030-06-01 · Advanced Gastric Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT07876414 · Groupe Oncologie Radiotherapie Tete et Cou
2027-02 – 2030-12 · Head and Neck Cancer Squamous Cell Carcinoma
What this study did
NCT06814067 · Fudan University
2025-02-10 – 2030-03-01 · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
What this study did
Hepatocellular Carcinoma
NCT05185739 · University College, London
2022-08-25 – 2030-07 · Hepatocellular Carcinoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT03632941 · Herbert Lyerly
2019-03-01 – 2024-06-26 · Breast Cancer, HER2+ Breast Cancer
What this study did
Melanoma
NCT06999980 · Melanoma Institute Australia
2026-02-09 – 2038-01 · Cutaneous Melanoma, Mucosal Melanoma
What this study did
NCT04462406 · ECOG-ACRIN Cancer Research Group
2021-02-09 – 2030-09-30 · Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
What this study did
NCT03070392 · Immunocore Ltd
2017-10-16 – 2025-09-17 · Uveal Melanoma
What this study did
NCT02054520 · NewLink Genetics Corporation
2014-06 – 2021-01-05 · Stage IV Melanoma, Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT07122687 · Innovent Biologics (Suzhou) Co. Ltd.
2025-08-26 – 2030-04-30 · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT05565378 · GlaxoSmithKline
2022-10-14 – 2027-12-06 · Lung Cancer, Non-Small Cell
What this study did
NCT04736173 · Arcus Biosciences, Inc.
2021-02-08 – 2026-09-17 · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
What this study did
NCT04581824 · GlaxoSmithKline
2020-11-19 – 2024-09-10 · Lung Cancer, Non-Small Cell
What this study did
NCT04252365 · Guangdong Association of Clinical Trials
2020-03-01 – 2021-12-01 · Nsclc
What this study did
Renal Cell Carcinoma
NCT05805501 · Hoffmann-La Roche
2023-04-21 – 2026-10-05 · Renal Cell Carcinoma
What this study did
Solid Tumors
NCT07793942 · Merck Sharp & Dohme LLC
2026-10-21 – 2030-07-28 · Malignant Neoplam, Advanced Solid Tumors
What this study did
Phase 1/2 (5)
Melanoma
NCT02872259 · Haukeland University Hospital
2017-02-13 – 2024-05-23 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06173505 · Xencor, Inc.
2023-12-27 – 2025-12-29 · Nonsquamous Non-small Cell Lung Cancer
What this study did
NCT05709821 · iOx Therapeutics
2023-11-15 – 2024-04-22 · Non-small Cell Lung Cancer, Melanoma
What this study did
Solid Tumors
NCT07095868 · Everest Medicines (Beijing) Co., Ltd.
2025-11-17 – 2031-11 · Selected Types of Solid Tumor
What this study did
Other / comorbidity
NCT02430363 · Medical Research Council
2013-03 – 2018-06 · Glioblastoma
What this study did
Phase 1 (6)
Melanoma
NCT06212388 · Xijing Hospital
2024-01-24 – 2028-10-30 · Melanoma
What this study did
NCT07581509 · Biocon Biologics UK PLC
2026-06-29 – 2028-06-21 · Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
What this study did
NCT07475572 · Alvotech Swiss AG
2026-08-10 – 2028-04-14 · Melanoma
What this study did
NCT06551064 · Formycon AG
2024-07-01 – 2026-07-07 · Melanoma, Stage II, Melanoma Stage III
What this study did
Solid Tumors
NCT03530397 · MedImmune LLC
2018-04-24 – 2027-11-30 · Selected Advanced Solid Tumors
What this study did
Other / comorbidity
NCT06173011 · Qilu Pharmaceutical Co., Ltd.
2023-12-12 – 2024-07 · Tumor
What this study did
Phase 4 (1)
Non-Small Cell Lung Cancer
NCT05689671 · Nikolaj Frost MD
2023-12-06 – 2026-10 · Non-Small Cell Lung Cancer Metastatic
What this study did
Appears in other studies (110)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (43)
Breast Cancer
NCT04335669 · Lund University Hospital
2019-12-20 – 2035-09 · Breast Cancer, Triple Negative Breast Neoplasms
What this study did
Gastric Cancer
NCT06901531 · Astellas Pharma Global Development, Inc.
2025-05-22 – 2028-09-30 · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
What this study did
Head and Neck Squamous Cell Carcinoma
NCT06525220 · Genmab
2024-09-25 – 2030-07 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05815927 · European Organisation for Research and Treatment of Cancer - EORTC
2025-05-23 – 2030-03-30 · Oligometastatic Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT04747054 · UNICANCER
2021-12-01 – 2029-10-01 · Squamous Cell Carcinoma of Head and Neck
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06966700 · Merck Sharp & Dohme LLC
2025-06-30 – 2034-12-29 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
What this study did
Melanoma
NCT05933577 · Merck Sharp & Dohme LLC
2023-07-19 – 2030-09-26 · Melanoma
What this study did
NCT05155254 · IO Biotech
2022-05-17 – 2027-09 · Metastatic Melanoma, Unresectable Melanoma
What this study did
NCT04657991 · Pfizer
2021-01-15 – 2026-10-30 · Melanoma
What this study did
NCT02263508 · Amgen
2014-12-08 – 2021-03-11 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06096844 · National Cancer Institute (NCI)
2024-07-19 – 2039-04-01 · Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
NCT06623422 · Merck Sharp & Dohme LLC
2024-10-21 – 2038-01-26 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT06077760 · Merck Sharp & Dohme LLC
2023-12-06 – 2035-12-21 · Non-small Cell Lung Cancer
What this study did
NCT07877584 · German Cancer Research Center
2026-11-30 – 2033-11-30 · Non-Small Cell Lung Cancer
What this study did
NCT05317858 · InSightec
2022-08-12 – 2031-12-01 · Brain Tumor, Non Small Cell Lung Cancer
What this study did
NCT07777822 · Revolution Medicines, Inc.
2026-08-14 – 2031-02 · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung Cancer (NSCLC), Metastatic NSCLC - Non-Small Cell Lung Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer
What this study did
NCT06119581 · Eli Lilly and Company
2023-12-21 – 2031-01 · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
What this study did
NCT07251582 · Hunan Province Tumor Hospital
2026-08-12 – 2029-05-31 · Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC)
What this study did
NCT06758401 · Pfizer
2025-07-23 – 2029-03-01 · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
What this study did
NCT06216301 · NovoCure GmbH
2024-07-31 – 2028-10 · Metastatic Non-small Cell Lung Cancer
What this study did
NCT04339218 · Institut Bergonié
2020-08-28 – 2028-08-27 · Lung Adenocarcinoma, Cryotherapy Effect
What this study did
NCT03774732 · UNICANCER
2018-01-24 – 2026-12-22 · Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4
What this study did
NCT06448312 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
2024-06-07 – 2026-11 · Non-Small Cell Lung Cancer
What this study did
NCT03976362 · Merck Sharp & Dohme LLC
2019-06-28 – 2026-01-30 · Carcinoma, Squamous Cell, Non-small-cell Lung
What this study did
NCT03302234 · Merck Sharp & Dohme LLC
2017-12-14 – 2022-09-07 · Carcinoma, Non-Small-Cell Lung
What this study did
Renal Cell Carcinoma
NCT06661720 · Alliance for Clinical Trials in Oncology
2025-03-14 – 2037-11 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
What this study did
NCT07383441 · SWOG Cancer Research Network
2026-06-05 – 2034-01-31 · Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
What this study did
Urothelial Carcinoma
NCT03361865 · Incyte Corporation
2017-12-04 – 2020-08-04 · UC (Urothelial Cancer)
What this study did
NCT03374488 · Incyte Corporation
2017-12-22 – 2020-07-23 · UC (Urothelial Cancer)
What this study did
Other / comorbidity
NCT07218380 · Eli Lilly and Company
2025-12-12 – 2033-05 · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
What this study did
Phase 2/3 (7)
Head and Neck Squamous Cell Carcinoma
NCT06295731 · Inhibrx Biosciences, Inc
2024-05-14 – 2031-05 · Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
What this study did
NCT06788990 · Bicara Therapeutics
2025-01-28 – 2029-07 · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
NCT04534205 · BioNTech SE
2021-01-07 – 2029-04 · Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
What this study did
NCT06082167 · Exelixis
2024-06-07 – 2029-03 · Head and Neck Squamous Cell Carcinoma
What this study did
Melanoma
NCT06697301 · Eikon Therapeutics
2025-05-22 – 2040-12 · Advanced Melanoma
What this study did
Merkel Cell Carcinoma
NCT06947928 · TuHURA Biosciences, Inc.
2025-12-11 – 2032-12-30 · Advanced Or Metastatic Merkel Cell Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07365319 · Eikon Therapeutics
2026-06-15 – 2040-12-31 · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
What this study did
Phase 2 (42)
Biliary Tract Cancer
NCT06502080 · Shanghai Zhongshan Hospital
2024-07 – 2028-06-30 · Biliary Tract Cancer
What this study did
Colorectal Cancer
NCT06006923 · Anwaar Saeed
2024-06-26 – 2025-11-12 · MSI-H Colorectal Cancer
What this study did
Head and Neck Squamous Cell Carcinoma
NCT04987996 · Providence Health & Services
2023-07-01 – 2031-07-01 · Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05980000 · Washington University School of Medicine
2023-10-27 – 2030-06-30 · Recurrent Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Metastatic Head and Neck Cancer, HNSCC
What this study did
NCT05913388 · Providence Health & Services
2024-02-29 – 2027-07 · Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05172258 · National Cancer Institute (NCI)
2022-07-26 – 2027-06-30 · Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
What this study did
NCT04675294 · ALX Oncology Inc.
2021-04-02 – 2026-06-30 · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
What this study did
NCT05323656 · Calliditas Therapeutics Suisse SA
2022-04-06 – 2025-08-21 · Squamous Cell Carcinoma of Head and Neck
What this study did
NCT03511391 · University Hospital, Ghent
2018-03-09 – 2024-01-23 · Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer, Head and Neck Cancer
What this study did
NCT05743777 · Canadian Cancer Trials Group
2023-05-12 – 2023-05-12 · Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT03771820 · NanoCarrier Co., Ltd.
2019-07-01 – 2022-04-30 · SCCHN
What this study did
Hepatocellular Carcinoma
NCT07157969 · Peking Union Medical College Hospital
2025-02-19 – 2027-06-30 · HCC - Hepatocellular Carcinoma
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05163223 · Aston Sci. Inc.
2022-02-28 – 2024-05-31 · Breast Cancer
What this study did
Melanoma
NCT03897881 · ModernaTX, Inc.
2019-07-18 – 2032-11-21 · Melanoma
What this study did
NCT06961006 · Merck Sharp & Dohme LLC
2025-05-29 – 2031-09-05 · Malignant Melanoma
What this study did
NCT03693014 · Memorial Sloan Kettering Cancer Center
2018-10-01 – 2027-10 · Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
What this study did
NCT04995094 · HiberCell, Inc.
2021-08-15 – 2023-05-18 · Pathologic Stage III Cutaneous Melanoma AJCC v8
What this study did
Merkel Cell Carcinoma
NCT03304639 · National Cancer Institute (NCI)
2018-06-12 – 2026-02-19 · Advanced Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Cutaneous Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
What this study did
Metastatic Colorectal Cancer
NCT05217446 · Pfizer
2022-07-11 – 2027-01-26 · Metastatic Colorectal Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07098988 · CatalYm GmbH
2025-08-01 – 2031-03-31 · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
What this study did
NCT07603856 · University of Chicago
2026-12-12 – 2030-06-25 · Non-Small Cell Lung Cancer, Metastatic Lung Cancer
What this study did
NCT06463665 · Genelux Corporation
2024-09-26 – 2029-07 · Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
What this study did
NCT03137771 · NRG Oncology
2017-04-07 – 2028-12 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT06132698 · West China Hospital
2023-11-30 – 2026-06-30 · NSCLC Associated With Leptomeningeal Metastases
What this study did
NCT04622007 · Effector Therapeutics
2021-06-02 – 2024-12-09 · Non-small Cell Lung Cancer
What this study did
NCT04139317 · Novartis Pharmaceuticals
2020-01-22 – 2023-02-07 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT04265534 · Calithera Biosciences, Inc
2020-07-24 – 2022-02-09 · Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Gene Mutation, NFE2L2 Gene Mutation
What this study did
NCT03322540 · Incyte Corporation
2017-12-15 – 2020-11-09 · Lung Cancer
What this study did
NCT03382899 · Eli Lilly and Company
2018-03-19 – 2020-03-05 · Non Small Cell Lung Cancer
What this study did
NCT02492568 · The Netherlands Cancer Institute
2015-07 – 2018-06 · Non-Small Cell Lung Cancer
What this study did
Renal Cell Carcinoma
NCT05327686 · NRG Oncology
2023-02-01 – 2033-06-15 · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
What this study did
NCT06307431 · Merck Sharp & Dohme LLC
2024-04-10 – 2032-06-08 · Renal Cell Carcinoma
What this study did
NCT07593040 · Vall d'Hebron Institute of Oncology
2027-01 – 2031-06 · Renal Cell Carcinoma
What this study did
NCT07928167 · Kidney Cancer Research Bureau
2025-08-25 – 2028-01-01 · Metastatic Renal Cell Carcinoma ( mRCC)
What this study did
Other / comorbidity
NCT06482801 · Second Affiliated Hospital of Guangzhou Medical University
2024-06-10 – 2035-12-30 · Liver Cancer, Antibody
What this study did
NCT06483347 · Second Affiliated Hospital of Guangzhou Medical University
2024-04-04 – 2033-12-30 · Lung Cancer, Inoperable Disease
What this study did
NCT07811193 · Vividion Therapeutics, Inc.
2026-09-11 – 2030-12-31 · Colorectal Adenocarcinoma
What this study did
NCT05814666 · Flamingo Therapeutics NV
2023-05-30 – 2025-08-14 · HNSCC
What this study did
NCT03018288 · National Cancer Institute (NCI)
2017-09-21 – 2022-12-20 · Glioblastoma
What this study did
Phase 1/2 (12)
Head and Neck Squamous Cell Carcinoma
NCT07213934 · University of Cincinnati
2025-10-08 – 2031-12 · Head and Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma
What this study did
Hepatocellular Carcinoma
NCT06896396 · Zhiyong Huang
2025-04-01 – 2028-02-01 · Unresectable Hepatocellular Carcinoma
What this study did
Melanoma
NCT02557321 · Provectus Biopharmaceuticals, Inc.
2015-10 – 2025-04 · Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT06644768 · Daiichi Sankyo
2024-10-30 – 2030-04-30 · Non-small Cell Lung Cancer, Lung Cancer
What this study did
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did
NCT02638090 · H. Lee Moffitt Cancer Center and Research Institute
2016-03-22 – 2027-06 · Lung Cancer, Non-small Cell Lung Cancer
What this study did
NCT05705466 · Kartos Therapeutics, Inc.
2023-06 – 2027-06 · Non Small Cell Lung Cancer
What this study did
NCT04585035 · InventisBio Co., Ltd
2020-10-02 – 2025-12 · Solid Tumor, Adult, NSCLC, CRC
What this study did
NCT03562871 · IO Biotech
2018-08-22 – 2022-04-12 · NSCLC
What this study did
Solid Tumors
NCT02843204 · Fuda Cancer Hospital, Guangzhou
2016-07-01 – 2019-07-01 · Malignant Solid Tumour
What this study did
Other / comorbidity
NCT06305767 · Merck Sharp & Dohme LLC
2024-03-28 – 2031-10-20 · Bladder Cancer
What this study did
NCT03126630 · National Cancer Institute (NCI)
2018-10-04 – 2027-02-25 · Pleural Malignant Mesothelioma
What this study did
Phase 1 (2)
Non-Small Cell Lung Cancer
NCT03732664 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2018-10-01 – 2023-03-23 · High-Risk Resectable NSCLC
What this study did
Ovarian Cancer
NCT04354246 · Compugen Ltd
2020-03-31 – 2026-04-01 · Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer, Plasma Cell Neoplasm, Multiple Myeloma, HNSCC, Microsatellite Stable Colorectal Carcinoma, MSS-CRC
What this study did
Early phase / not applicable (4)
Endometrial Cancer
NCT06549855 · Peking University People's Hospital
2024-09-02 – 2029-10 · Endometrial Cancer, Endometrioid Carcinoma, Mismatch Repair Deficiency
What this study did
Esophageal Squamous Cell Carcinoma
NCT07067450 · Sichuan University
2025-07-20 – 2026-12-31 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Hepatocellular Carcinoma
NCT05339581 · RenJi Hospital
2022-05-20 – 2024-05-31 · Liver Cancer, Liver Transplant; Complications, Hepatocellular Carcinoma, Portal Vein Thrombosis, Radiotherapy; Complications
What this study did
Other / comorbidity
NCT06676293 · Chang Gung Memorial Hospital
2023-08-01 – 2024-08-01 · Nasopharyngeal Carcinoma (NPC)
What this study did

Competitive landscape

This mechanism is crowded: 26 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pembrolizumab: this drugApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
AdebrelimabPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
AlmonertinibPhase 3Small moleculeEGFRPartial signal
NCT04500717: ACROSS 2 in stage IIIB-IV NSCLC with EGFR sensitizing mutations and tumor suppressor gene mutations: median PFS 19.78 months (aumolertinib plus carboplatin/pemetrexed) versus 16.53 months (aumolertinib monotherapy); HR 0.55 (95% CI: 0.339-0.910; p=0.0205).
AndamertinibPhase 3Small moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
ApatinibPhase 3Small moleculeVEGFR2Partial signal
NCT01270386: Primary (PFS): median 4.7 vs 1.9 months, apatinib vs placebo, significantly improved; ORR 12.2% vs 0%; DCR 69% vs 24%.
APG-2449Phase 3Small moleculeFAK / ALK / ROS1not yet gradedNo reviewed efficacy summary in this indication
BAT3306Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
BecotatugPhase 3Monoclonal antibodyEGFRPartial signal
NCT06380348: Primary endpoint, IRC-assessed progression-free survival vs platinum-pemetrexed: met at a prespecified interim analysis (2026-09-24).
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
CabozantinibPhase 3Small moleculeMET / VEGFR / AXL / RET (multi-kinase)Partial signal
NCT04471428: Overall Survival (OS) (Up to approximately 24 months): Atezolizumab + Cabozantinib 10.7 months (95% CI 8.8 to 12.3) vs Docetaxel Monotherapy 10.5 months (95% CI 8.6 to 13) missed
CadonilimabPhase 3Multispecific antibodyPD-1×CTLA-4Weak signalNo reviewed efficacy summary in this indication
CamrelizumabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported.
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
CT-P51Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DostarlimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed
EnlonstobartPhase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
FamitinibPhase 3Small moleculec-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3not yet gradedNo reviewed efficacy summary in this indication
HLX04 (Hanbeitai)Phase 3Monoclonal antibodyVEGF-APartial signal
NCT03952403: ASTRUM-002 met the primary endpoint of progression-free survival with the combination of serplulimab plus HLX04 (bevacizumab biosimilar) and chemotherapy at interim analysis. A total of 636 patients were randomized 1:1:1 to serplulimab plus HLX04 and chemotherapy (group A), serplulimab plus HLX04 placebo and chemotherapy (group B), or double placebo plus chemotherapy (group C). Serplulimab plus chemotherapy significantly prolonged OS and maintained the PFS benefit compared to chemotherapy; however, the addition of the bevacizumab biosimilar HLX04 did not yield further improvement for first-line treatment of nonsquamous NSCLC.
IBI305Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT02954172: Objective response rate at 18 weeks: 44.3% IBI305 (n=221) vs 46.4% bevacizumab (n=220); odds ratio 0.90 (90% CI 0.756–1.077), prespecified equivalence margin 0.75–1.33.
IBI363Phase 3Multispecific antibodyPD-1 x IL-2Rα (IL2RA)not yet gradedNo reviewed efficacy summary in this indication
INCA33890
Phase 3(overall)
Multispecific antibodyTGF-βR2 and PD-1 (conditional bispecific)not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
Iparomlimab (QL1604)
Phase 3(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Iparomlimab And TuvonralimabPhase 3Multispecific antibodyPD-1 x CTLA-4not yet gradedNo reviewed efficacy summary in this indication
IvonescimabPhase 3Multispecific antibodyPD-1 + VEGFAReliable signal
NCT05499390: HARMONi-2 (NCT05499390), independent-review PFS at the interim analysis: ivonescimab 11.1 vs pembrolizumab 5.8 months; HR 0.51 (95% CI 0.38-0.69), one-sided p<0.0001; 398 randomized
NCT05184712: HARMONi-A (NCT05184712), independent-review PFS: ivonescimab plus chemotherapy 7.1 vs placebo plus chemotherapy 4.8 months; HR 0.46 (95% CI 0.34-0.62), P<.001
IzalontamabPhase 3Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
LY01008Phase 3Monoclonal antibodyVEGF-AReliable signal
NCT03533127: LY01008 vs Avastin (bevacizumab) + paclitaxel/carboplatin, first-line non-squamous NSCLC: ORR 48.5% vs 53.0%; stratified ORR ratio 0.91 (90% CI 0.80-1.04), within prespecified equivalence margin 0.75-1.33 -> equivalence/non-inferiority demonstrated.
MB12Phase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
NiraparibPhase 3Small moleculePARP1/2Partial signal
NCT04475939: Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population (Up to 52 months): Niraparib + Pembrolizumab 5.55 Months (95% CI 4.14 to 8.28) vs Placebo + Pembrolizumab 5.55 Months (95% CI 4.21 to 7.16) missed
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
PenpulimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met.
PF-08634404Phase 3Multispecific antibodyPD-1 + VEGFnot yet gradedNo reviewed efficacy summary in this indication
RelatlimabPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
RetifanlimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7)
Retlirafusp AlfaPhase 3Multispecific antibodyPD-L1 and TGF-beta (TGF-βRII trap)Partial signalNo reviewed efficacy summary in this indication
RilvegostomigPhase 3Multispecific antibodyPD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
S-1Phase 3Small moleculeThymidylate synthase (via 5-FU, released from tegafur) and dihydropyrimidine dehydrogenase (inhibited by gimeracil)not yet gradedNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Savolitinib (Orpathys)Phase 3Small moleculeMETPartial signal
NCT05261399: SAFFRON (NCT05261399): osimertinib plus savolitinib showed a statistically significant and clinically meaningful improvement in both PFS and OS vs platinum-based doublet chemotherapy in EGFRm NSCLC patients who progressed on osimertinib.
NCT05015608: Median PFS (SACHI trial, ITT): 8.2 months savolitinib+osimertinib vs 4.5 months chemotherapy; in patients prior on 1st/2nd-gen EGFR-TKI: 9.8 vs 5.4 months; predefined significance thresholds met in both populations
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
SintilimabPhase 3Monoclonal antibodyPD-1Partial signal
NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022).
NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2)
Sotiburafusp AlfaPhase 3Multispecific antibodyPD-L1 / VEGFnot yet gradedNo reviewed efficacy summary in this indication
Telisotuzumab AdizutecanPhase 3Antibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
ToripalimabPhase 3Monoclonal antibodyPD-1Reliable signal
NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met.
NCT03856411: Median PFS: 8.4 months (toripalimab plus chemotherapy) vs 5.6 months (placebo plus chemotherapy); HR 0.49 (95% CI 0.39-0.61), P<0.0001
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
VolrustomigPhase 3Multispecific antibodyPD-1 x CTLA-4Partial signal
NCT05984277: Dual primary endpoints (PFS and OS) not expected to be met: the IDMC concluded the volrustomig combination was unlikely to meet either, and AstraZeneca is discontinuing the trial (2026-08-17). missed
BudigalimabPhase 2/3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
SasanlimabPhase 2/3Monoclonal antibodyPD-1Partial signalFeatured results are dose-finding only in this race
BalstilimabPhase 2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
BotensilimabPhase 2Monoclonal antibodyCTLA-4not yet gradedNo reviewed efficacy summary in this indication
Brentuximab VedotinPhase 2Antibody–drug conjugateAnti-CD30 antibody-drug conjugateWeak signal
NCT04609566: Confirmed ORR, brentuximab vedotin + pembrolizumab (SGN35-033): NSCLC cohort 8% primary-refractory (n=12) / 14% secondary-refractory (n=43); melanoma cohort 18% primary-refractory (n=17) / 24% secondary-refractory (n=41)
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
Erdafitinib (Balversa)Phase 2Small moleculeFGFR1-4Weak signal
NCT02699606: NSCLC cohort (n=12): objective response rate 0% (no CR or PR); disease control rate 25.0% (95% CI 5.5-57.2%); 3 patients stable disease, 2 with tumor shrinkage >20%. missed
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NBTXR3Phase 2NanoparticleHafnium-oxide nanoparticle radioenhancernot yet gradedNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
Notiretatug RezetecanPhase 2Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
Olvimulogene NanivacirepvecPhase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
OrdastobartPhase 2Monoclonal antibodyOX40 (agonist)not yet gradedNo reviewed efficacy summary in this indication
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Raludotatug DeruxtecanPhase 2Antibody–drug conjugateCDH6 (Cadherin-6)not yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045
Phase 2(overall)
UndisclosedPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
Tisotumab Vedotin Humax-Tf-Adc (Tivdak)Phase 2Antibody–drug conjugateTissue Factor (TF)Weak signalFeatured results are dose-finding only in this race
TUB-040Phase 2Antibody–drug conjugateNaPi2b (sodium-dependent phosphate transporter, SLC34A2)not yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
UbamatamabPhase 2Monoclonal antibodyMUC16 x CD3not yet gradedNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
ZanzalintinibPhase 2Small moleculeVEGFR2; MET; AXL; MER; TYRO3not yet gradedNo reviewed efficacy summary in this indication
A2B530Phase 1/2Cell therapyCEA / carcinoembryonic antigen (activator) / HLA-A*02 (blocker)not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication
ASP546CPhase 1/2Antibody–drug conjugateClaudin 18.2 (CLDN18.2)not yet gradedNo reviewed efficacy summary in this indication
BGB-B2033Phase 1/2Multispecific antibodyGPC3 (glypican-3) x 4-1BB (CD137)not yet gradedNo reviewed efficacy summary in this indication
CetrelimabPhase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
DSP107Phase 1/2Protein / enzyme therapeuticSIRP-alpha/4-1BBL fusion proteinnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
GI-101APhase 1/2Protein / enzyme therapeuticCTLA-4 / IL-2Rβγnot yet gradedNo reviewed efficacy summary in this indication
IOV-4001Phase 1/2Cell therapyPD-1not yet gradedNo reviewed efficacy summary in this indication
N-DihydrogalactochitosanPhase 1/2PolysaccharideSTING and inflammasome pathwaysnot yet gradedNo reviewed efficacy summary in this indication
NilvanstomigPhase 1/2Biologic (subtype unspecified)PD-1 and TIGITnot yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
OSE-279Phase 1/2Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Ozuriftamab VedotinPhase 1/2Antibody–drug conjugateROR2Partial signalNo reviewed efficacy summary in this indication
Precemtabart TocentecanPhase 1/2Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
Puxitatug SamrotecanPhase 1/2Antibody–drug conjugateB7-H4not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
ABBV-324Phase 1Antibody–drug conjugateGlypican-3 (GPC3) / Topoisomerase Inot yet gradedNo reviewed efficacy summary in this indication
AfivastobartPhase 1Monoclonal antibodyCD39 (ENTPD1)not yet gradedNo reviewed efficacy summary in this indication
AKY-1189Phase 1RadiopharmaceuticalNectin-4 (PVRL4)not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Bmab1700
Phase 1(overall)
Monoclonal antibodyPD-1
not yet graded(overall)
No reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
Ixotatug VedotinPhase 1Antibody–drug conjugateClaudin 6 (CLDN6)not yet gradedNo reviewed efficacy summary in this indication
KRAS-Specific Autologous TCR-T CellPhase 1Cell therapyKRAS G12V presented on HLA-A*11:01not yet gradedNo reviewed efficacy summary in this indication
LY4052031Phase 1Antibody–drug conjugateNectin-4not yet gradedNo reviewed efficacy summary in this indication
LY4066434
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
ONO-4578Phase 1Small moleculeProstaglandin E2 receptor 4 (EP4)not yet gradedNo reviewed efficacy summary in this indication
PalupiprantPhase 1Small moleculeEP4Weak signalNo reviewed efficacy summary in this indication
PF-07934040
Phase 1(overall)
Small moleculePan-KRASnot yet gradedNo reviewed efficacy summary in this indication
Sofetabart MipitecanPhase 1Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
Tusamitamab SonditecanPhase 1Antibody–drug conjugateCEACAM5not yet gradedNo reviewed efficacy summary in this indication
BuparlisibDiscontinuedSmall moleculePI3K inhibitor (pan-class I)not yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 180 furthest-along competitors are listed; 433 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(713 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pembrolizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (74)
November 2026 (6)
Phase 2Differentiated Thyroid CancerRecruiting
Est. primary completion 2026-11 · NCT05852223 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-11-23 · NCT06545331 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-11-25 · NCT02955290 · CT.gov ↗
What to watch
Phase 1Anal Cancer Stage III A, Anal Cancer Stage III BActive not recruiting
Est. primary completion 2026-11-30 · NCT04046133 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT05093231 · CT.gov ↗
What to watch
Phase 2Chordomas, ChordomaRecruiting
Est. primary completion 2026-11-30 · NCT06794645 · CT.gov ↗
What to watch
December 2026 (68)
Phase 2MelanomaActive not recruiting
Est. primary completion 2026-12 · NCT02644369 · CT.gov ↗
What to watch
Phase 2Adenoid Cystic Carcinoma, Salivary Gland CancerActive not recruiting
Est. primary completion 2026-12 · NCT04209660 · CT.gov ↗
What to watch
Phase 2Lymphoma, Extranodal NK-T-CellActive not recruiting
Est. primary completion 2026-12 · NCT04417166 · CT.gov ↗
What to watch
Phase 1Malignant Epithelial NeoplasmsActive not recruiting
Est. primary completion 2026-12 · NCT04520711 · CT.gov ↗
What to watch
Early phase / not applicableHead and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05047094 · CT.gov ↗
What to watch
Phase 1Cervical CancerActive not recruiting
Est. primary completion 2026-12 · NCT05082259 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic SarcomaRecruiting
Est. primary completion 2026-12 · NCT05182164 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05319015 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2026-12 · NCT05378425 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12 · NCT05645380 · CT.gov ↗
What to watch
Early phase / not applicableMalignant AscitesEnrolling by invitation
Est. primary completion 2026-12 · NCT05745233 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05784688 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2026-12 · NCT05785754 · CT.gov ↗
What to watch
Phase 2Sinonasal Undifferentiated CarcinomaRecruiting
Est. primary completion 2026-12 · NCT05925491 · CT.gov ↗
What to watch
Phase 2Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary SyndromeRecruiting
Est. primary completion 2026-12 · NCT05956041 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT05977907 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12 · NCT06178445 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06211335 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06246110 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12 · NCT06580054 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2026-12 · NCT06640283 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12 · NCT06711900 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2026-12-01 · NCT03030378 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT05420948 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12-01 · NCT05491226 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06161545 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-01 · NCT06998069 · CT.gov ↗
What to watch
Phase 1/2Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed CancerRecruiting
Est. primary completion 2026-12-05 · NCT04421560 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2026-12-09 · NCT04164082 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2026-12-11 · NCT04879329 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-15 · NCT04585750 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-15 · NCT05669430 · CT.gov ↗
What to watch
Phase 2Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm, Malignant Ureter Neoplasm …Recruiting
Est. primary completion 2026-12-16 · NCT05756569 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2026-12-20 · NCT06793761 · CT.gov ↗
What to watch
Phase 2Uterine Carcinosarcoma, Advanced Uterine CarcinosarcomaActive not recruiting
Est. primary completion 2026-12-23 · NCT05147558 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2026-12-24 · NCT05701527 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT03362060 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaActive not recruiting
Est. primary completion 2026-12-30 · NCT03419481 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT04699123 · CT.gov ↗
What to watch
Phase 1Gastric CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT05041153 · CT.gov ↗
What to watch
Phase 1Lymphoma, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06475235 · CT.gov ↗
What to watch
Phase 1Follicular LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03361852 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03383094 · CT.gov ↗
What to watch
Phase 3Merkel Cell CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03712605 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT03804944 · CT.gov ↗
What to watch
Phase 2/3Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04093167 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04140526 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT04265872 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT04443088 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04708418 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT04754321 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05180097 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05286437 · CT.gov ↗
What to watch
Phase 2Hodgkin's LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT05355051 · CT.gov ↗
What to watch
Phase 1/2Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05491083 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT05496036 · CT.gov ↗
What to watch
Phase 1/2Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2026-12-31 · NCT05514990 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT05675579 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaRecruiting
Est. primary completion 2026-12-31 · NCT05679921 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06052839 · CT.gov ↗
What to watch
Phase 1/2Endometrial CancerRecruiting
Est. primary completion 2026-12-31 · NCT06253494 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06324240 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT06415487 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT06513624 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06907602 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT07136545 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT07162883 · CT.gov ↗
What to watch
2027 (272)
January 2027 (28)
Early phase / not applicableGlioma, Recurrent Malignant GliomaActive not recruiting
Est. primary completion 2027-01 · NCT02658279 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01 · NCT03313206 · CT.gov ↗
What to watch
Phase 1Mesothelioma, Malignant, PD-L1 Negative, Advanced Cancer, Progressive DiseaseActive not recruiting
Est. primary completion 2027-01 · NCT03546426 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01 · NCT04561362 · CT.gov ↗
What to watch
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)Active not recruiting
Est. primary completion 2027-01 · NCT04666740 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT04683679 · CT.gov ↗
What to watch
Phase 2GliomaRecruiting
Est. primary completion 2027-01 · NCT05188508 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-01 · NCT06045195 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-01 · NCT03244384 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT04134559 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT05775471 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-01 · NCT06731270 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-01-01 · NCT06904573 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-07 · NCT05493566 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-01-09 · NCT04616248 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-11 · NCT04938609 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-01-12 · NCT05609968 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-21 · NCT05366166 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-29 · NCT05911295 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-29 · NCT06246968 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-01-30 · NCT06549946 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-30 · NCT07376317 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-01-31 · NCT04079166 · CT.gov ↗
What to watch
Phase 3Urinary Bladder NeoplasmsActive not recruiting
Est. primary completion 2027-01-31 · NCT04241185 · CT.gov ↗
What to watch
Phase 2Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial Neoplasia 2Active not recruiting
Est. primary completion 2027-01-31 · NCT04712851 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT05114421 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-01-31 · NCT05406713 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2027-01-31 · NCT05761951 · CT.gov ↗
What to watch
February 2027 (13)
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2027-02 · NCT02287428 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-02 · NCT03832569 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-02 · NCT05382286 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02 · NCT06228326 · CT.gov ↗
What to watch
Phase 1Mesotheliomas PleuralRecruiting
Est. primary completion 2027-02-01 · NCT03760575 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2027-02-01 · NCT04724018 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-02-12 · NCT03407144 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-02-12 · NCT06492759 · CT.gov ↗
What to watch
Phase 2Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-02-20 · NCT03995147 · CT.gov ↗
What to watch
Phase 2Adrenocortical CarcinomaActive not recruiting
Est. primary completion 2027-02-28 · NCT05036434 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-02-28 · NCT05120596 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-02-28 · NCT06047379 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-02-28 · NCT07180862 · CT.gov ↗
What to watch
March 2027 (17)
Phase 2Advanced SarcomaActive not recruiting
Est. primary completion 2027-03 · NCT04784247 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-03 · NCT04855435 · CT.gov ↗
What to watch
Phase 2Endometrial CancerNot yet recruiting
Est. primary completion 2027-03 · NCT05106127 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-03 · NCT05186974 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerActive not recruiting
Est. primary completion 2027-03 · NCT05271318 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-03 · NCT06400160 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-03 · NCT07215637 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07501650 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma Multiforme, Anaplastic Astrocytoma, GliosarcomaRecruiting
Est. primary completion 2027-03-01 · NCT05084430 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2027-03-10 · NCT06637306 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-03-15 · NCT05231122 · CT.gov ↗
What to watch
Phase 2Solid TumorsActive not recruiting
Est. primary completion 2027-03-22 · NCT04976634 · CT.gov ↗
What to watch
Phase 1Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin NeoplasmActive not recruiting
Est. primary completion 2027-03-31 · NCT04387084 · CT.gov ↗
What to watch
Phase 2Grade I Meningioma, Adult, Grade II Meningioma, Adult, Grade III Meningioma, Adult, Recurrent MeningiomaActive not recruiting
Est. primary completion 2027-03-31 · NCT04659811 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-03-31 · NCT04701476 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2027-03-31 · NCT05422794 · CT.gov ↗
What to watch
Early phase / not applicableMelanomaRecruiting
Est. primary completion 2027-03-31 · NCT07422779 · CT.gov ↗
What to watch
April 2027 (23)
Phase 1/2Chronic Lymphocytic Leukemia, Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-04 · NCT03153202 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-04 · NCT03504163 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04 · NCT04956640 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-04 · NCT05270213 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-04 · NCT05410145 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2027-04 · NCT06377566 · CT.gov ↗
What to watch
Phase 1Merkel Cell CarcinomaRecruiting
Est. primary completion 2027-04 · NCT06940440 · CT.gov ↗
What to watch
Phase 1/2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-04 · NCT07255664 · CT.gov ↗
What to watch
Phase 2Sarcoma, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Alveolar Soft Part SarcomaRecruiting
Est. primary completion 2027-04-01 · NCT04332874 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-01 · NCT04468061 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT06407310 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-08 · NCT04317534 · CT.gov ↗
What to watch
Phase 1Malignant Epithelial NeoplasmsActive not recruiting
Est. primary completion 2027-04-15 · NCT05349890 · CT.gov ↗
What to watch
Phase 2Anal CancerRecruiting
Est. primary completion 2027-04-15 · NCT06493019 · CT.gov ↗
What to watch
Phase 2B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-04-24 · NCT06242834 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-27 · NCT06364917 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT02414269 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT03589339 · CT.gov ↗
What to watch
Phase 1/2MelanomaActive not recruiting
Est. primary completion 2027-04-30 · NCT04971499 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-30 · NCT05492682 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-04-30 · NCT05537740 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-04-30 · NCT06102395 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-04-30 · NCT07160335 · CT.gov ↗
What to watch
May 2027 (21)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT05589818 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT05856981 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06465069 · CT.gov ↗
What to watch
Phase 2Renal CancerRecruiting
Est. primary completion 2027-05 · NCT06962787 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2027-05 · NCT06978114 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2027-05 · NCT07054567 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-01 · NCT05358548 · CT.gov ↗
What to watch
Phase 2Cervical CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT02628067 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2027-05-21 · NCT05132504 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-05-25 · NCT05440708 · CT.gov ↗
What to watch
Phase 3Endometrial NeoplasmsActive not recruiting
Est. primary completion 2027-05-27 · NCT05173987 · CT.gov ↗
What to watch
Phase 1/2Lung CancerRecruiting
Est. primary completion 2027-05-30 · NCT05886439 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-05-31 · NCT02600949 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-31 · NCT05085028 · CT.gov ↗
What to watch
Phase 2Adrenocortical CarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT05563467 · CT.gov ↗
What to watch
Phase 2Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate CarcinomaRecruiting
Est. primary completion 2027-05-31 · NCT05766371 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-05-31 · NCT05845814 · CT.gov ↗
What to watch
Phase 1Colorectal CancerRecruiting
Est. primary completion 2027-05-31 · NCT06004245 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT07159217 · CT.gov ↗
What to watch
June 2027 (32)
Phase 2Brain MetastasesActive not recruiting
Est. primary completion 2027-06 · NCT02886585 · CT.gov ↗
What to watch
Phase 2Lymphoma, Relapsed, RefractoryActive not recruiting
Est. primary completion 2027-06 · NCT03179930 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03546686 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06 · NCT05239624 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06 · NCT05585320 · CT.gov ↗
What to watch
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2027-06 · NCT05633654 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-06 · NCT05732831 · CT.gov ↗
What to watch
Phase 1Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-06 · NCT05733689 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-06 · NCT05978102 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-06 · NCT06353997 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06 · NCT06906822 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2027-06 · NCT07484022 · CT.gov ↗
What to watch
Phase 1CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT04485013 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-01 · NCT05777603 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT06439836 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-06-01 · NCT06576037 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07332351 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2027-06-01 · NCT07412054 · CT.gov ↗
What to watch
Phase 1Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous Cell Carcinoma …Recruiting
Est. primary completion 2027-06-05 · NCT06912087 · CT.gov ↗
What to watch
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2027-06-06 · NCT05934448 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-06-11 · NCT05319730 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-16 · NCT04389632 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT03505320 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03854474 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05030506 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05034536 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-06-30 · NCT05096663 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT05405595 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-06-30 · NCT06634875 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-30 · NCT06942234 · CT.gov ↗
What to watch
July 2027 (23)
Phase 1Lung CancerActive not recruiting
Est. primary completion 2027-07 · NCT03220477 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-07 · NCT03546582 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-07 · NCT03829254 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-07 · NCT04427293 · CT.gov ↗
What to watch
Phase 2Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome, Sezary Syndrome, Sézary, Advanced Mycosis FungoidesActive not recruiting
Est. primary completion 2027-07 · NCT04960618 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-07 · NCT05524935 · CT.gov ↗
What to watch
Phase 2SCLC,Extensive StageRecruiting
Est. primary completion 2027-07 · NCT05623319 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-07 · NCT05970497 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-07 · NCT07188246 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2027-07 · NCT07591597 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-01 · NCT05570825 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-07-11 · NCT06312176 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsNot yet recruiting
Est. primary completion 2027-07-13 · NCT07843550 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-14 · NCT06205706 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2027-07-19 · NCT07187778 · CT.gov ↗
What to watch
Phase 2Small Cell Lung Cancer Extensive StageActive not recruiting
Est. primary completion 2027-07-30 · NCT05384015 · CT.gov ↗
What to watch
Phase 2Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-07-30 · NCT05507541 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-30 · NCT05878691 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-07-30 · NCT06635824 · CT.gov ↗
What to watch
Phase 1Lymphocytic LeukemiaRecruiting
Est. primary completion 2027-07-31 · NCT03219450 · CT.gov ↗
What to watch
Phase 2CholangiocarcinomaRecruiting
Est. primary completion 2027-07-31 · NCT05967182 · CT.gov ↗
What to watch
Phase 2Triple-Negative Breast NeoplasmNot yet recruiting
Est. primary completion 2027-07-31 · NCT07011823 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-07-31 · NCT07061964 · CT.gov ↗
What to watch
August 2027 (22)
Phase 2Hodgkin Lymphoma, Relapsed or Refractory Hodgkin LymphomaRecruiting
Est. primary completion 2027-08 · NCT03618550 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-08 · NCT05020860 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08 · NCT05081609 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-08 · NCT05462496 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-08 · NCT05901285 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-08 · NCT06027268 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-08 · NCT06057038 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerActive not recruiting
Est. primary completion 2027-08 · NCT06116136 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-08 · NCT06234397 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08 · NCT06917079 · CT.gov ↗
What to watch
Phase 2Erythroleukoplakia, Leukoplakia, Verrucous Oral LeukoplakiaRecruiting
Est. primary completion 2027-08-01 · NCT03603223 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-01 · NCT05894889 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-08-03 · NCT06545682 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-08-03 · NCT06880549 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-08-11 · NCT04069273 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-08-12 · NCT07486817 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsActive not recruiting
Est. primary completion 2027-08-13 · NCT05438329 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-08-30 · NCT05205109 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT06951399 · CT.gov ↗
What to watch
Phase 2Metastatic Thyroid Gland Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 …Active not recruiting
Est. primary completion 2027-08-31 · NCT04171622 · CT.gov ↗
What to watch
Phase 1Colorectal CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05838768 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-08-31 · NCT06806852 · CT.gov ↗
What to watch
September 2027 (16)
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
Phase 2Colorectal Adenocarcinoma Metastatic in the LiverRecruiting
Est. primary completion 2027-09 · NCT07082439 · CT.gov ↗
What to watch
Early phase / not applicableBiliary Tract CancerRecruiting
Est. primary completion 2027-09 · NCT07853690 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-09-01 · NCT04253964 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-09-01 · NCT06366347 · CT.gov ↗
What to watch
Phase 2Autologous Stem Cell Transplant, Classic Hodgkin LymphomaRecruiting
Est. primary completion 2027-09-01 · NCT06377540 · CT.gov ↗
What to watch
Phase 1Recurrent Group 3 Medulloblastoma, Recurrent Group 4 (Non-SHH/Non-WNT) MedulloblastomaRecruiting
Est. primary completion 2027-09-01 · NCT06514898 · CT.gov ↗
What to watch
Early phase / not applicableUrothelial CarcinomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07629700 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT03793179 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT05746897 · CT.gov ↗
What to watch
Phase 2Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT05799144 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-09-30 · NCT06083844 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT06318897 · CT.gov ↗
What to watch
Phase 1Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT06600321 · CT.gov ↗
What to watch
Phase 1/2Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-09-30 · NCT07327229 · CT.gov ↗
What to watch
October 2027 (18)
Phase 1/2Prostate CancerRecruiting
Est. primary completion 2027-10 · NCT04946370 · CT.gov ↗
What to watch
Phase 2Bellini Carcinoma, Collecting Duct Carcinoma, Renal Medullary CarcinomaRecruiting
Est. primary completion 2027-10 · NCT06302569 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10 · NCT06561685 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-10 · NCT07207395 · CT.gov ↗
What to watch
Phase 2NPC, Locoregionally Advanced Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2027-10 · NCT07267338 · CT.gov ↗
What to watch
Phase 2Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell TumorsRecruiting
Est. primary completion 2027-10-01 · NCT06041503 · CT.gov ↗
What to watch
Phase 3Solid TumorsRecruiting
Est. primary completion 2027-10-01 · NCT07174453 · CT.gov ↗
What to watch
Phase 2Classical Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-03 · NCT05404945 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-05 · NCT05544929 · CT.gov ↗
What to watch
Phase 2Neuroendocrine TumorsActive not recruiting
Est. primary completion 2027-10-15 · NCT06232564 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-10-20 · NCT06845319 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-28 · NCT04624204 · CT.gov ↗
What to watch
Phase 2Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar CancerRecruiting
Est. primary completion 2027-10-30 · NCT05903833 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-30 · NCT05922904 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-10-30 · NCT05929235 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-10-31 · NCT04429542 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-10-31 · NCT05907980 · CT.gov ↗
What to watch
November 2027 (15)
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-11 · NCT04219254 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11 · NCT06772623 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2027-11 · NCT06809140 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-11 · NCT07276880 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06667167 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-11-21 · NCT03313778 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-30 · NCT04297605 · CT.gov ↗
What to watch
Phase 2Solid TumorsActive not recruiting
Est. primary completion 2027-11-30 · NCT05642780 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-11-30 · NCT06108050 · CT.gov ↗
What to watch
Phase 2Gastric CancerRecruiting
Est. primary completion 2027-11-30 · NCT06123338 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-11-30 · NCT06142617 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-11-30 · NCT06994806 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-11-30 · NCT07261683 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-11-30 · NCT07455032 · CT.gov ↗
What to watch
Phase 2Muscle-invasive Bladder CancerRecruiting
Est. primary completion 2027-11-30 · NCT07475806 · CT.gov ↗
What to watch
December 2027 (44)
Phase 1CLL, B-cell Non Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-12 · NCT03283137 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT03556228 · CT.gov ↗
What to watch
Phase 2Esophageal Adenocarcinoma, Gastric AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT04150640 · CT.gov ↗
What to watch
Phase 2Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary DiseaseRecruiting
Est. primary completion 2027-12 · NCT04645602 · CT.gov ↗
What to watch
Phase 2Cervical CancerRecruiting
Est. primary completion 2027-12 · NCT04865887 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma MultiformeRecruiting
Est. primary completion 2027-12 · NCT04977375 · CT.gov ↗
What to watch
Phase 3Endometrial CancerNot yet recruiting
Est. primary completion 2027-12 · NCT05077215 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT05431270 · CT.gov ↗
What to watch
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2027-12 · NCT05482893 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2027-12 · NCT05547321 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT06086288 · CT.gov ↗
What to watch
Phase 2Colon CancerNot yet recruiting
Est. primary completion 2027-12 · NCT06646445 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12 · NCT06694350 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-12 · NCT06771544 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07227168 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT07264816 · CT.gov ↗
What to watch
Early phase / not applicableOral Cavity CancerRecruiting
Est. primary completion 2027-12 · NCT07343596 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-12 · NCT07565285 · CT.gov ↗
What to watch
Phase 2Prostate Cancer, High-risk Prostate CancerRecruiting
Est. primary completion 2027-12-01 · NCT07027124 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-12-02 · NCT05568550 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-12-02 · NCT07158918 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-12-06 · NCT06795412 · CT.gov ↗
What to watch
Phase 2Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma …Recruiting
Est. primary completion 2027-12-16 · NCT06006013 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2027-12-27 · NCT06502743 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT05438420 · CT.gov ↗
What to watch
Phase 2Endometrial CancerActive not recruiting
Est. primary completion 2027-12-30 · NCT06180733 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-30 · NCT06736379 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02717156 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT03225664 · CT.gov ↗
What to watch
Phase 1Stage III Thymoma AJCC v8, Stage IIIA Thymoma AJCC v8, Stage IIIB Thymoma AJCC v8, Stage IV Thymoma AJCC v8, Stage IVA Thymoma AJCC v8 …Recruiting
Est. primary completion 2027-12-31 · NCT03295227 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT03319940 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT04729322 · CT.gov ↗
What to watch
Phase 1MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT04930783 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05726370 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT06049212 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT06636734 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT06846268 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT06920810 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
Phase 2Nasopharyngeal Cancer Recurrent, Nasopharyngeal Cancinoma (NPC)Not yet recruiting
Est. primary completion 2027-12-31 · NCT07129772 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT07469774 · CT.gov ↗
What to watch
Phase 1/2MelanomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07817901 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07862751 · CT.gov ↗
What to watch
2028 (162)
January 2028 (18)
Phase 2Soft Tissue Sarcoma Adult, Angiosarcoma, Undifferentiated Pleomorphic SarcomaRecruiting
Est. primary completion 2028-01 · NCT05961761 · CT.gov ↗
What to watch
Phase 2Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06160843 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerActive not recruiting
Est. primary completion 2028-01 · NCT06699836 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01 · NCT06725368 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaNot yet recruiting
Est. primary completion 2028-01 · NCT07217496 · CT.gov ↗
What to watch
Phase 2Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma …Recruiting
Est. primary completion 2028-01 · NCT07283822 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 1Post-Acute COVID-19 SyndromeNot yet recruiting
Est. primary completion 2028-01-01 · NCT07388550 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-05 · NCT05208762 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-01-10 · NCT06311721 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 2Pancreatic Ductal AdenocarcinomaRecruiting
Est. primary completion 2028-01-20 · NCT06831136 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-01-25 · NCT06170788 · CT.gov ↗
What to watch
Phase 1MelanomaActive not recruiting
Est. primary completion 2028-01-31 · NCT03311308 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-01-31 · NCT04752826 · CT.gov ↗
What to watch
Phase 2Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any SiteRecruiting
Est. primary completion 2028-01-31 · NCT05746208 · CT.gov ↗
What to watch
Phase 1/2Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8Recruiting
Est. primary completion 2028-01-31 · NCT06470282 · CT.gov ↗
What to watch
Phase 1Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT06868433 · CT.gov ↗
What to watch
February 2028 (13)
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-02 · NCT06719362 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2028-02 · NCT07652242 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-02 · NCT07807345 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2028-02-02 · NCT02332668 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-02-08 · NCT07914309 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-02-15 · NCT06747585 · CT.gov ↗
What to watch
Phase 2Solid TumorsRecruiting
Est. primary completion 2028-02-16 · NCT07415031 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-02-28 · NCT05064280 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-02-28 · NCT06462794 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-28 · NCT06472583 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02-28 · NCT07287917 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-02-28 · NCT07404332 · CT.gov ↗
What to watch
Phase 4Solid TumorsNot yet recruiting
Est. primary completion 2028-02-29 · NCT06824792 · CT.gov ↗
What to watch
March 2028 (21)
Phase 2Metastatic Pancreatic CancerNot yet recruiting
Est. primary completion 2028-03 · NCT04901741 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-03 · NCT05232409 · CT.gov ↗
What to watch
Phase 3MelanomaRecruiting
Est. primary completion 2028-03 · NCT05549297 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT05578664 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2028-03 · NCT06109467 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03 · NCT06225596 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT06356155 · CT.gov ↗
What to watch
Phase 1/2Localized Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-03 · NCT06384560 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03 · NCT06579196 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-03 · NCT07183319 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03 · NCT07807163 · CT.gov ↗
What to watch
Phase 3MelanomaRecruiting
Est. primary completion 2028-03-01 · NCT05727904 · CT.gov ↗
What to watch
Phase 2Colorectal CancerNot yet recruiting
Est. primary completion 2028-03-01 · NCT07409844 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-03-08 · NCT05782361 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-23 · NCT03412877 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma, the Nasal Cavity, Paranasal SinusesRecruiting
Est. primary completion 2028-03-30 · NCT05027633 · CT.gov ↗
What to watch
Phase 1/2Advanced Malignant TumorsRecruiting
Est. primary completion 2028-03-30 · NCT06877650 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-31 · NCT05269381 · CT.gov ↗
What to watch
Phase 2Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-03-31 · NCT06381154 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT06483334 · CT.gov ↗
What to watch
Phase 1Breast CancerRecruiting
Est. primary completion 2028-03-31 · NCT07341867 · CT.gov ↗
What to watch
April 2028 (11)
Phase 1/2Locally Advanced or Metastatic HER2-Expressing CancersRecruiting
Est. primary completion 2028-04 · NCT05356741 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaRecruiting
Est. primary completion 2028-04 · NCT05733715 · CT.gov ↗
What to watch
Phase 2/3Progressive Multifocal LeukoencephalopathyNot yet recruiting
Est. primary completion 2028-04 · NCT06276504 · CT.gov ↗
What to watch
Phase 2Esophageal Adenocarcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2028-04 · NCT06340711 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-04 · NCT07458347 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2028-04-10 · NCT07634380 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-04-18 · NCT07094113 · CT.gov ↗
What to watch
Phase 2Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma …Recruiting
Est. primary completion 2028-04-30 · NCT04919629 · CT.gov ↗
What to watch
Phase 2T-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT05313243 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2028-04-30 · NCT07455019 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT07465276 · CT.gov ↗
What to watch
May 2028 (9)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-05 · NCT03526835 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-05 · NCT07128303 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-05 · NCT07484139 · CT.gov ↗
What to watch
Phase 1MelanomaRecruiting
Est. primary completion 2028-05-04 · NCT05859074 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-05-15 · NCT04348747 · CT.gov ↗
What to watch
Phase 2Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Metastatic Prostate Small Cell Carcinoma …Active not recruiting
Est. primary completion 2028-05-31 · NCT04471974 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2028-05-31 · NCT05101070 · CT.gov ↗
What to watch
Phase 1Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2028-05-31 · NCT05365581 · CT.gov ↗
What to watch
Phase 2Ovarian Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-05-31 · NCT05737199 · CT.gov ↗
What to watch
June 2028 (18)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-06 · NCT05656235 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06 · NCT05786924 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-06 · NCT06001658 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Mismatch Repair DeficiencyNot yet recruiting
Est. primary completion 2028-06-01 · NCT07385846 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-11 · NCT06902272 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-15 · NCT07845786 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-06-16 · NCT02621021 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2028-06-24 · NCT05853367 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-06-26 · NCT07282509 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT04977453 · CT.gov ↗
What to watch
Phase 1Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma …Recruiting
Est. primary completion 2028-06-30 · NCT04995003 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT05485766 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT05741164 · CT.gov ↗
What to watch
Phase 3Non-Muscle Invasive Bladder CancerRecruiting
Est. primary completion 2028-06-30 · NCT06545955 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06822543 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-06-30 · NCT06868732 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT07254585 · CT.gov ↗
What to watch
July 2028 (14)
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 1SarcomaRecruiting
Est. primary completion 2028-07 · NCT06113809 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-07 · NCT06284590 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07 · NCT06789172 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07 · NCT06882174 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-07 · NCT07915037 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2028-07-01 · NCT05923190 · CT.gov ↗
What to watch
Phase 1Urothelial CarcinomaEnrolling by invitation
Est. primary completion 2028-07-01 · NCT06204614 · CT.gov ↗
What to watch
Phase 4Urothelial CarcinomaRecruiting
Est. primary completion 2028-07-01 · NCT06764095 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2028-07-01 · NCT07198074 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-07-08 · NCT07090499 · CT.gov ↗
What to watch
Phase 3Non-Muscle Invasive Bladder CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT03711032 · CT.gov ↗
What to watch
Phase 1Gastric CancerRecruiting
Est. primary completion 2028-07-31 · NCT05187182 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-07-31 · NCT05581004 · CT.gov ↗
What to watch
August 2028 (9)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-08 · NCT05973864 · CT.gov ↗
What to watch
Early phase / not applicableUrothelial CarcinomaRecruiting
Est. primary completion 2028-08 · NCT07548476 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07634094 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08 · NCT07809256 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-08-04 · NCT05797168 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-08-07 · NCT07087860 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-08-15 · NCT07420439 · CT.gov ↗
What to watch
Phase 2Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual DiseaseActive not recruiting
Est. primary completion 2028-08-31 · NCT03516279 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2028-08-31 · NCT07639450 · CT.gov ↗
What to watch
September 2028 (10)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-09 · NCT06699212 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2028-09 · NCT07197827 · CT.gov ↗
What to watch
Phase 2Metastatic Malignant Neoplasm to Brain, Recurrent Brain Metastases, Progressive Brain MetastasesRecruiting
Est. primary completion 2028-09-01 · NCT02896335 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-01 · NCT07016399 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2028-09-01 · NCT07221942 · CT.gov ↗
What to watch
Phase 3Colorectal CancerActive not recruiting
Est. primary completion 2028-09-19 · NCT05239741 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-09-30 · NCT07407920 · CT.gov ↗
What to watch
Phase 2HNSCCRecruiting
Est. primary completion 2028-09-30 · NCT07668154 · CT.gov ↗
What to watch
Phase 2Anal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-09-30 · NCT07680088 · CT.gov ↗
What to watch
October 2028 (12)
Phase 2Breast CancerRecruiting
Est. primary completion 2028-10 · NCT04230109 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-10 · NCT07123415 · CT.gov ↗
What to watch
Phase 1Ovarian CancerNot yet recruiting
Est. primary completion 2028-10 · NCT07772882 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-10 · NCT07850791 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-13 · NCT07223047 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-10-16 · NCT06551142 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-10-20 · NCT05086692 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2028-10-24 · NCT07037004 · CT.gov ↗
What to watch
Phase 2Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2028-10-30 · NCT04675710 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-10-30 · NCT05952453 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-10-31 · NCT04613596 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07691476 · CT.gov ↗
What to watch
November 2028 (5)
Phase 2Phase 2, Zanzalintinib, Pembrolizumab, Advanced/Metastatic, Soft-Tissue SarcomaRecruiting
Est. primary completion 2028-11-01 · NCT07283731 · CT.gov ↗
What to watch
Phase 2/3Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable, Borderline ResectableRecruiting
Est. primary completion 2028-11-06 · NCT06923475 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-11-15 · NCT07932067 · CT.gov ↗
What to watch
Phase 2Angiosarcoma of Skin, Angiosarcoma MetastaticRecruiting
Est. primary completion 2028-11-30 · NCT06673628 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT06793215 · CT.gov ↗
What to watch
December 2028 (22)
Phase 1/2GlioblastomaActive not recruiting
Est. primary completion 2028-12 · NCT04121455 · CT.gov ↗
What to watch
Phase 2Malignant Pleural MesotheliomaNot yet recruiting
Est. primary completion 2028-12 · NCT05425576 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT05579366 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT05583708 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT06137378 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07020221 · CT.gov ↗
What to watch
Phase 2SarcomaRecruiting
Est. primary completion 2028-12 · NCT07089992 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07360743 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2028-12-01 · NCT06894459 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-01 · NCT07017829 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-21 · NCT07410676 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-27 · NCT01174121 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2028-12-30 · NCT06055465 · CT.gov ↗
What to watch
Phase 2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-12-30 · NCT06492408 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-30 · NCT06492421 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Carcinoma of Unknown Primary, Metastatic Adrenal Gland Pheochromocytoma …Active not recruiting
Est. primary completion 2028-12-31 · NCT02721732 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT03449238 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2028-12-31 · NCT05382559 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07622186 · CT.gov ↗
What to watch
Phase 1Rectal Cancer PatientsRecruiting
Est. primary completion 2028-12-31 · NCT07687875 · CT.gov ↗
What to watch
Phase 3Resectable Liposarcoma, Resectable Soft Tissue Sarcoma, Resectable Undifferentiated Pleomorphic SarcomaNot yet recruiting
Est. primary completion 2028-12-31 · NCT07823491 · CT.gov ↗
What to watch
2029 (95)
January 2029 (12)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01 · NCT05098132 · CT.gov ↗
What to watch
Phase 3Metastatic Non-squamous Lung CancerRecruiting
Est. primary completion 2029-01 · NCT05692999 · CT.gov ↗
What to watch
Phase 1/2HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCCRecruiting
Est. primary completion 2029-01 · NCT06016920 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-01 · NCT06045767 · CT.gov ↗
What to watch
Phase 2Primary GlioblastomaNot yet recruiting
Est. primary completion 2029-01 · NCT07347210 · CT.gov ↗
What to watch
Phase 2MelanomaNot yet recruiting
Est. primary completion 2029-01 · NCT07883759 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaRecruiting
Est. primary completion 2029-01-01 · NCT06004336 · CT.gov ↗
What to watch
Phase 1Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-01-01 · NCT07686744 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-01-12 · NCT06422143 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-01-15 · NCT07610525 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-01-31 · NCT07552558 · CT.gov ↗
What to watch
February 2029 (7)
Phase 2/3MelanomaRecruiting
Est. primary completion 2029-02 · NCT06624644 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2029-02 · NCT07643519 · CT.gov ↗
What to watch
Phase 2Carcinoma, Squamous Cell of Head and Neck HNSCCNot yet recruiting
Est. primary completion 2029-02 · NCT07840456 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07857486 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2029-02-23 · NCT07166601 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaActive not recruiting
Est. primary completion 2029-02-26 · NCT05562830 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerEnrolling by invitation
Est. primary completion 2029-02-28 · NCT07218003 · CT.gov ↗
What to watch
March 2029 (10)
Phase 2Gastric CancerRecruiting
Est. primary completion 2029-03 · NCT07176312 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2029-03 · NCT07262619 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2029-03 · NCT07740941 · CT.gov ↗
What to watch
Phase 2Carcinoma, Squamous Cell, Anorectal CancerRecruiting
Est. primary completion 2029-03-26 · NCT06669572 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2029-03-27 · NCT06843447 · CT.gov ↗
What to watch
Phase 2Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2029-03-30 · NCT05651594 · CT.gov ↗
What to watch
Phase 1/2Merkel Cell CarcinomaRecruiting
Est. primary completion 2029-03-30 · NCT07302347 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2029-03-31 · NCT05394103 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2029-03-31 · NCT05721755 · CT.gov ↗
What to watch
Phase 2/3Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin LymphomaNot yet recruiting
Est. primary completion 2029-03-31 · NCT07572123 · CT.gov ↗
What to watch
April 2029 (7)
Phase 3GlioblastomaActive not recruiting
Est. primary completion 2029-04 · NCT06556563 · CT.gov ↗
What to watch
Phase 1Metastatic Castration-resistant Prostate Cancer (mCRPC)Recruiting
Est. primary completion 2029-04 · NCT07244393 · CT.gov ↗
What to watch
Phase 2Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2029-04 · NCT07840001 · CT.gov ↗
What to watch
Phase 1/2Advanced MalignanciesRecruiting
Est. primary completion 2029-04-02 · NCT07644039 · CT.gov ↗
What to watch
Phase 2Anaplastic Thyroid Carcinoma, Thyroid Cancer, Thyroid CarcinomaNot yet recruiting
Est. primary completion 2029-04-08 · NCT07886905 · CT.gov ↗
What to watch
Phase 1Recurrent Endometrial Carcinoma, Unresectable Endometrial CarcinomaRecruiting
Est. primary completion 2029-04-15 · NCT05603910 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-04-30 · NCT06632327 · CT.gov ↗
What to watch
May 2029 (9)
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-05 · NCT05318573 · CT.gov ↗
What to watch
Phase 2Hodgkin LymphomaRecruiting
Est. primary completion 2029-05 · NCT06812858 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-05 · NCT06835569 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05 · NCT07633613 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITLRecruiting
Est. primary completion 2029-05-03 · NCT06137144 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-05-11 · NCT05555732 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2029-05-15 · NCT07349303 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2029-05-26 · NCT06480552 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-05-31 · NCT07889232 · CT.gov ↗
What to watch
June 2029 (7)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06245889 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT06400472 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT07452224 · CT.gov ↗
What to watch
Phase 2Large B-Cell LymphomaRecruiting
Est. primary completion 2029-06-01 · NCT06863402 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-06-18 · NCT07276399 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-06-30 · NCT04671667 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2029-06-30 · NCT07287995 · CT.gov ↗
What to watch
July 2029 (5)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-02 · NCT07221474 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2029-07-16 · NCT07667335 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-07-23 · NCT07684599 · CT.gov ↗
What to watch
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
Phase 2Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin LymphomaRecruiting
Est. primary completion 2029-07-31 · NCT07021989 · CT.gov ↗
What to watch
August 2029 (4)
Early phase / not applicableCervical CancerRecruiting
Est. primary completion 2029-08 · NCT04555226 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2029-08 · NCT06960395 · CT.gov ↗
What to watch
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2029-08-31 · NCT03228667 · CT.gov ↗
What to watch
September 2029 (10)
Phase 3Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06081244 · CT.gov ↗
What to watch
Phase 2/3Urothelial CarcinomaRecruiting
Est. primary completion 2029-09 · NCT06493552 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-09 · NCT06976944 · CT.gov ↗
What to watch
Phase 1/2Biliary Tract CancerNot yet recruiting
Est. primary completion 2029-09 · NCT07269158 · CT.gov ↗
What to watch
Phase 2Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma …Recruiting
Est. primary completion 2029-09-01 · NCT07301268 · CT.gov ↗
What to watch
Phase 1/2Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal CancerRecruiting
Est. primary completion 2029-09-12 · NCT06469944 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-09-22 · NCT07743190 · CT.gov ↗
What to watch
Phase 2Colon CancerRecruiting
Est. primary completion 2029-09-30 · NCT07808151 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2029-09-30 · NCT07888816 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-09-30 · NCT07890714 · CT.gov ↗
What to watch
October 2029 (13)
Phase 2Recurrent GlioblastomaRecruiting
Est. primary completion 2029-10 · NCT06558214 · CT.gov ↗
What to watch
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07368985 · CT.gov ↗
What to watch
Phase 1Ewing Sarcoma, Desmoplastic Small Round Cell TumorNot yet recruiting
Est. primary completion 2029-10 · NCT07695311 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07744126 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-10 · NCT07773987 · CT.gov ↗
What to watch
Phase 3Gastric CancerNot yet recruiting
Est. primary completion 2029-10-01 · NCT06093425 · CT.gov ↗
What to watch
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2029-10-01 · NCT07908979 · CT.gov ↗
What to watch
Phase 1/2Biliary Tract CancerRecruiting
Est. primary completion 2029-10-16 · NCT06428409 · CT.gov ↗
What to watch
Phase 2Classic Hodgkin LymphomaRecruiting
Est. primary completion 2029-10-20 · NCT07275216 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10-30 · NCT05187338 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2029-10-30 · NCT05957081 · CT.gov ↗
What to watch
Phase 2Angiosarcoma, Angiosarcoma, AdultRecruiting
Est. primary completion 2029-10-31 · NCT06898970 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-10-31 · NCT07786428 · CT.gov ↗
What to watch
November 2029 (3)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2029-11 · NCT07732634 · CT.gov ↗
What to watch
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2029-11-01 · NCT05197322 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-11-15 · NCT07252739 · CT.gov ↗
What to watch
December 2029 (8)
Phase 2MelanomaNot yet recruiting
Est. primary completion 2029-12 · NCT06976021 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07910942 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CarcinomaActive not recruiting
Est. primary completion 2029-12-10 · NCT04938817 · CT.gov ↗
What to watch
Phase 1Solid TumorsNot yet recruiting
Est. primary completion 2029-12-30 · NCT06724042 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
Phase 2Cervical Adenocarcinoma, Cervical Adenosquamous CarcinomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT06805864 · CT.gov ↗
What to watch
Phase 1Cancer-NeoplasmsRecruiting
Est. primary completion 2029-12-31 · NCT07610941 · CT.gov ↗
What to watch
Phase 1/2Intrahepatic Cholangiocarcinoma (Icc)Not yet recruiting
Est. primary completion 2029-12-31 · NCT07632235 · CT.gov ↗
What to watch
2030 (46)
January 2030 (5)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-01 · NCT06607185 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01 · NCT06745882 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-01-31 · NCT04267848 · CT.gov ↗
What to watch
Phase 4Neoplasm Malignant, Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma, Biliary Tract Carcinoma, Uterine Cervical NeoplasmsNot yet recruiting
Est. primary completion 2030-01-31 · NCT07801027 · CT.gov ↗
What to watch
Phase 2Ovarian Clear Cell CarcinomaNot yet recruiting
Est. primary completion 2030-01-31 · NCT07913568 · CT.gov ↗
What to watch
February 2030 (4)
Phase 1/2Muscle Invasive Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8Recruiting
Est. primary completion 2030-02-01 · NCT07579195 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-02-10 · NCT07619599 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-02-25 · NCT05067283 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2030-02-28 · NCT07730021 · CT.gov ↗
What to watch
March 2030 (3)
Phase 3Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-03-04 · NCT05215340 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-03-18 · NCT07182591 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-03-31 · NCT07566156 · CT.gov ↗
What to watch
April 2030 (4)
Phase 2Urothelial CarcinomaActive not recruiting
Est. primary completion 2030-04 · NCT03547973 · CT.gov ↗
What to watch
Phase 3Colorectal CancerRecruiting
Est. primary completion 2030-04-05 · NCT07750158 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-04-30 · NCT05719558 · CT.gov ↗
What to watch
May 2030 (3)
Phase 4Cervical CancerRecruiting
Est. primary completion 2030-05 · NCT07645625 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2030-05-18 · NCT06841354 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerActive not recruiting
Est. primary completion 2030-05-31 · NCT05200559 · CT.gov ↗
What to watch
June 2030 (3)
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-06 · NCT06270706 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Junction (GEJ) AdenocarcinomaRecruiting
Est. primary completion 2030-06 · NCT07018570 · CT.gov ↗
What to watch
Phase 2Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma …Recruiting
Est. primary completion 2030-06-01 · NCT07783581 · CT.gov ↗
What to watch
July 2030 (6)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2030-07 · NCT05131919 · CT.gov ↗
What to watch
Phase 2Cutaneous SarcomaRecruiting
Est. primary completion 2030-07 · NCT07007273 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2030-07 · NCT07046923 · CT.gov ↗
What to watch
Phase 2Betel-nut-associated Oral CarcinomaNot yet recruiting
Est. primary completion 2030-07 · NCT07733466 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2030-07-17 · NCT07751042 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-31 · NCT07739966 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-08-31 · NCT05954312 · CT.gov ↗
What to watch
September 2030 (5)
Phase 3MelanomaRecruiting
Est. primary completion 2030-09 · NCT06488482 · CT.gov ↗
What to watch
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2030-09 · NCT07762703 · CT.gov ↗
What to watch
Phase 1/2Glioblastoma (GBM)Not yet recruiting
Est. primary completion 2030-09 · NCT07762716 · CT.gov ↗
What to watch
Phase 4Renal Cell CarcinomaRecruiting
Est. primary completion 2030-09-24 · NCT07872553 · CT.gov ↗
What to watch
Phase 1Breast CancerNot yet recruiting
Est. primary completion 2030-09-30 · NCT07300475 · CT.gov ↗
What to watch
October 2030 (1)
Phase 1/2Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma …Active not recruiting
Est. primary completion 2030-10-28 · NCT05920798 · CT.gov ↗
What to watch
November 2030 (2)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-11-30 · NCT07223424 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-11-30 · NCT07859592 · CT.gov ↗
What to watch
December 2030 (9)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
Phase 3Advanced Bladder CancerNot yet recruiting
Est. primary completion 2030-12 · NCT07346053 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2030-12 · NCT07485296 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2030-12-01 · NCT06146777 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2030-12-01 · NCT07247110 · CT.gov ↗
What to watch
Phase 3Breast CancerRecruiting
Est. primary completion 2030-12-16 · NCT06393374 · CT.gov ↗
What to watch
Phase 3Urothelial CarcinomaRecruiting
Est. primary completion 2030-12-31 · NCT06524544 · CT.gov ↗
What to watch
Phase 3Cervical CancerRecruiting
Est. primary completion 2030-12-31 · NCT07061977 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07890493 · CT.gov ↗
What to watch
2031 (27)
January 2031 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2031-01-24 · NCT03725059 · CT.gov ↗
What to watch
Phase 1/2Cervical CancerRecruiting
Est. primary completion 2031-01-31 · NCT06543576 · CT.gov ↗
What to watch
February 2031 (4)
Phase 2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-02 · NCT07172256 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-02-26 · NCT06618287 · CT.gov ↗
What to watch
Phase 3Gastric CancerRecruiting
Est. primary completion 2031-02-28 · NCT07673887 · CT.gov ↗
What to watch
Phase 2Advanced Laryngeal Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Stage III Laryngeal Cancer AJCC v8 …Not yet recruiting
Est. primary completion 2031-02-28 · NCT07923877 · CT.gov ↗
What to watch
March 2031 (1)
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2031-03-31 · NCT07749586 · CT.gov ↗
What to watch
April 2031 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-04 · NCT06343402 · CT.gov ↗
What to watch
Phase 2Urothelial Bladder CancerNot yet recruiting
Est. primary completion 2031-04-01 · NCT07663747 · CT.gov ↗
What to watch
June 2031 (2)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2031-06-26 · NCT06134375 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2031-06-30 · NCT06384352 · CT.gov ↗
What to watch
July 2031 (3)
Phase 1Solid TumorsRecruiting
Est. primary completion 2031-07 · NCT06724016 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2031-07-01 · NCT04990921 · CT.gov ↗
What to watch
Phase 1/2Urothelial CarcinomaRecruiting
Est. primary completion 2031-07-08 · NCT07232602 · CT.gov ↗
What to watch
August 2031 (3)
Phase 2ccRCCNot yet recruiting
Est. primary completion 2031-08 · NCT07460206 · CT.gov ↗
What to watch
Phase 2/3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-08-12 · NCT07063745 · CT.gov ↗
What to watch
Phase 2Endometrial CancerRecruiting
Est. primary completion 2031-08-31 · NCT07594015 · CT.gov ↗
What to watch
September 2031 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2031-09-01 · NCT05155033 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-09-30 · NCT07509099 · CT.gov ↗
What to watch
October 2031 (3)
Phase 2Vulva CancerRecruiting
Est. primary completion 2031-10 · NCT07290894 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2031-10-22 · NCT07660094 · CT.gov ↗
What to watch
Phase 3Cervical CancerRecruiting
Est. primary completion 2031-10-29 · NCT07216703 · CT.gov ↗
What to watch
November 2031 (1)
Phase 3Bladder CancerRecruiting
Est. primary completion 2031-11-17 · NCT07829783 · CT.gov ↗
What to watch
December 2031 (4)
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2031-12 · NCT04541108 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2031-12-01 · NCT07720180 · CT.gov ↗
What to watch
Phase 1Solid TumorsRecruiting
Est. primary completion 2031-12-03 · NCT07204340 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2031-12-31 · NCT06006650 · CT.gov ↗
What to watch
2032 (19)
January 2032 (4)
Phase 2Breast CancerRecruiting
Est. primary completion 2032-01-01 · NCT06078384 · CT.gov ↗
What to watch
Phase 3Renal Cell CarcinomaNot yet recruiting
Est. primary completion 2032-01-01 · NCT07689240 · CT.gov ↗
What to watch
Phase 1/2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-01-04 · NCT06780111 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-01-29 · NCT05789082 · CT.gov ↗
What to watch
February 2032 (4)
Phase 2Urothelial CarcinomaRecruiting
Est. primary completion 2032-02-01 · NCT06770582 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2032-02-06 · NCT06788912 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-02-13 · NCT04165070 · CT.gov ↗
What to watch
Phase 1/2Solid TumorsRecruiting
Est. primary completion 2032-02-18 · NCT05533697 · CT.gov ↗
What to watch
March 2032 (3)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-03-12 · NCT06731907 · CT.gov ↗
What to watch
Phase 1Solid TumorsNot yet recruiting
Est. primary completion 2032-03-30 · NCT07905924 · CT.gov ↗
What to watch
Phase 1/2Gastric CancerRecruiting
Est. primary completion 2032-03-31 · NCT05438459 · CT.gov ↗
What to watch
April 2032 (3)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2032-04 · NCT07486687 · CT.gov ↗
What to watch
Phase 3Metastatic Dedifferentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma …Recruiting
Est. primary completion 2032-04-18 · NCT06422806 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2032-04-30 · NCT04114136 · CT.gov ↗
What to watch
May 2032 (2)
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2032-05-24 · NCT06952504 · CT.gov ↗
What to watch
December 2032 (3)
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-12 · NCT07026474 · CT.gov ↗
What to watch
Phase 3Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-12-25 · NCT06589804 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2032-12-27 · NCT06385080 · CT.gov ↗
What to watch
2033 (7)
January 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-01-01 · NCT06606730 · CT.gov ↗
What to watch
March 2033 (2)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-03-31 · NCT05929768 · CT.gov ↗
What to watch
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2033-03-31 · NCT07178730 · CT.gov ↗
What to watch
April 2033 (1)
Phase 2Head and Neck Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2033-04 · NCT06557889 · CT.gov ↗
What to watch
July 2033 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2/3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2033-11-01 · NCT03755739 · CT.gov ↗
What to watch
December 2033 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2033-12 · NCT07015853 · CT.gov ↗
What to watch
2034 (3)
February 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-02-21 · NCT06312137 · CT.gov ↗
What to watch
August 2034 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2034-08-22 · NCT07513376 · CT.gov ↗
What to watch
November 2034 (1)
Phase 2Urothelial CarcinomaNot yet recruiting
Est. primary completion 2034-11 · NCT07822373 · CT.gov ↗
What to watch
2035 (1)
September 2035 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2035-09 · NCT07552181 · CT.gov ↗
What to watch
2036 (2)
September 2036 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2036-09 · NCT07718854 · CT.gov ↗
What to watch
December 2036 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2036-12-31 · NCT05669846 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
2040 (3)
February 2040 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2040-02-28 · NCT07770100 · CT.gov ↗
What to watch
June 2040 (1)
Phase 1/2Biliary Cancer, Bile Duct Cancer, Cancer of the Bile DuctRecruiting
Est. primary completion 2040-06-01 · NCT05849480 · CT.gov ↗
What to watch
December 2040 (1)
Phase 1MelanomaActive not recruiting
Est. primary completion 2040-12 · NCT04483778 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
Phase 3Solid TumorsRecruiting
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(8)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

21 October 2026ApprovalEC approves KEYTRUDA plus Padcev perioperatively in resectable MIBC
EU, EC · Source ↗
17 August 2026FDA action datePDUFA target action date set
US, FDA · Source ↗
20 April 2026Filing acceptedFDA accepts sBLA for PADCEV + Keytruda perioperative MIBC
US, FDA · Source ↗
20 April 2026Priority reviewFDA grants Priority Review to PADCEV + Keytruda sBLA
US, FDA · Source ↗
7 April 2026FDA action datePDUFA target action date set for April 7, 2026
US, FDA · Source ↗
17 December 2025Topline resultEV-304/KEYNOTE-B15 Phase 3 topline results positive
18 October 2025Topline resultEV-303/KEYNOTE-905 Phase 3 positive results for PADCEV plus KEYTRUDA
8 January 2025ApprovalNMPA approves PADCEV with KEYTRUDA for advanced urothelial cancer
CN, NMPA · Source ↗